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ABSTRACT
Ovarian cancer is the most lethal of the gynecological malignancies with the highest incidence rates in the
developed countries. Unfortunately, the incidence rates have been increasing in many Western countries.
Although the past decades have brought some advancements in the treatment and thus some improvement
in the survival, the prognosis of ovarian cancer patients still remains bleak. Therefore, additional tools to
achieve a more precise assessment of prognosis are required to identify those patients that could gain
benefit from more aggressive treatment.
   The aim of this retrospective study was to evaluate the prognostic significance of clinicopathological
and biological factors related to cell adhesion and angiogenesis in epithelial ovarian carcinoma. The
material of the study consisted of 310 women diagnosed and treated for epithelial ovarian malignancy in
Kuopio University Hospital and Jyväskylä Central Hospital, Finland, between 1976 and 1992, with a
follow-up until January 2004. The expression patterns for versican, E-cadherin, ?- and ?-catenins, iNOS
and CD34 were determined by means of immunohistochemistry, and quantification of angiogenesis was
performed by the Chalkley method. The associations of these biological markers were investigated with
relation to the previously assessed hyaluronan, CD44 and ?-catenin expression as well as to the
clinicopathological features and the survival of patients.
   Versican expression in ovarian cancer stroma was frequent and thus different from the normal ovarian
stroma, and furthermore cancer cell-associated versican expression was noted in tumour epithelium but
not detected in epithelial cells of normal ovary. The levels of E-cadherin and ?-catenin on cancer cell
membrane were reduced in poorly differentiated carcinomas. In addition, nuclear expression of ?-catenin
was seen especially in endometrioid and ?-catenin in serous ovarian cancers, whereas high iNOS
expression was typical for the mucinous histological subtype and a low Chalkley count was associated
with serous and clear cell histological subtypes.
   Increasing stromal versican expression predicted poorer disease-related survival in the univariate
analysis during the first five years, but not any longer after ten years of follow-up. The recurrence-free
survival at ten years was significantly better when the tumour epithelium was versican positive. The
previously defined independent prognostic value of stromal hyaluronan expression was confirmed.
Nuclear expressions of ?-catenin and ?-catenin were significant prognosticators of better outcome in the
univariate analysis of endometrioid tumours, as were also preserved membranous expressions of E-
cadherin and ?-catenin in the whole study cohort, but none of these factors possessed independent
prognostic value for epithelial ovarian cancer outcome. High iNOS expression was associated with a
better disease-related survival in the univariate analysis, whereas it did not retain its statistical
significance in the multivariate analysis. A high Chalkley count was a significant and independent
predictor of poor survival.
   In conclusion, besides confirming the independent prognostic significance of conventional
clinicopathological factors such as primary residual tumour and histological subtype, these results suggest
that the determination of angiogenesis by the Chalkley count can provide additional prognostic value in
epithelial ovarian cancer.
National Library of Medicine Classification: WP 322, QZ 206
Medical Subject Headings: ovarian neoplasms; neoplasms, glandular and epithelial; carcinoma;
prognosis; survival rate; immunohistochemistry; cell adhesion; neovascularization, pathologic; versicans;
cadherins; catenins; nitric oxide synthase type II; antigens, CD34
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1. INTRODUCTION
Ovarian cancer is the fifth most common cancer in women and the leading cause of
mortality from the gynecologic cancers in Finland, resulting in approximately 300
deaths annually (1). Worldwide, approximately 125 000 women died of ovarian cancer
in 2002 (2). The incidence rates are highest in developed countries, especially in
northern Europe (2). A slight increase in incidence of ovarian cancer has occurred
during the past decades in Finland, with an incidence of 10.2 per 100 000 women and a
total of 486 new diagnoses made in 2004, excluding borderline tumours of the ovary
(1).
   The majority of ovarian cancers are diagnosed only when there is distant spread of the
disease (3), leading to a bleak prognosis for the patients. The relative 5-year survival
rate in Finland is 49% (4). Some improvement in the overall survival of the patients
with ovarian cancer has been achieved during recent decades (5) due to the
advancement of surgical treatment and platinum-based chemotherapy regimens (6).
However, the prognosis of patients with apparently similar conventional prognostic
factors is variable and difficult to predict. An improved understanding of ovarian cancer
biology would make it easier to predict the disease outcome and help to select those
patients who would benefit from different treatments. In addition, it could provide new
targets for therapeutic interventions.
   In the present study, the expression and the prognostic value of several factors related
to cell adhesion (versican, E-cadherin, ?- and ?-catenins) and angiogenesis (iNOS,
CD34) were evaluated in epithelial ovarian cancer.
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2. REVIEW OF THE LITERATURE
2.1. Epidemiology of epithelial ovarian cancer
Ovarian cancer is the sixth most common cancer and the seventh cause of death from
cancer in women worldwide, accounting for approximately 125 000 deaths annually on
a global basis. The highest incidence rates are observed in northern and western Europe
as well as in northern America (2). The general view in Europe is that there is a slowly
increasing trend in ovarian cancer incidence, particularly in older women. In terms of
age-standardised mortality, there seems to be a declining trend (7). In Finland, the age-
adjusted incidence rate of ovarian cancer was 10.2 per 100 000 person-years in 2004.
During the same year, 486 new ovarian cancer cases and 302 deaths due to ovarian
cancer were reported, i.e. the age-adjusted ovarian cancer mortality was 5.3 per 100 000
person-years (1).
2.2. Etiology, risk factors and progression of epithelial ovarian cancer
The origin of epithelial ovarian cancer is believed to be malignant transformation of
ovarian surface epithelium, which undergoes repetitive rupture and repair at the time of
ovulation (8, 9). There are several, not mutually exclusive, hypotheses attempting to
explain the development of ovarian cancer lesions; these include the incessant ovulation
hypothesis (10), the gonadotropin hypothesis (11), the hormonal hypothesis (12), and
the inflammation hypothesis (13). The incessant ovulation hypothesis proposes that
continuous damage of the ovarian surface epithelium, followed by proliferation of
surface epithelial cells after ovulation may increase the probability of mutations and
thus lead to an increased risk of developing epithelial ovarian cancer (10, 14). The
gonadotropin hypothesis postulates that exposure to high levels of gonadotropins may
be the trigger for malignant transformation, probably by enhancing cell growth and
inhibiting apoptosis either directly or indirectly through estrogenic stimulation of
ovarian surface epithelium (11, 14, 15). Furthermore, the hormonal hypothesis claims
that excess androgen stimulation leads to increased epithelial ovarian cancer risk, which
in turn may be decreased by progesterone stimulation (12, 14). Finally, the
inflammation hypothesis starts from the assumption that ovarian tumourigenesis may be
17
enhanced in response to genetic damage caused by the inflammatory factors, such as
those deriving from environmental factors, endometriosis, genital tract infections, or the
ovulatory process itself (13, 14).
   A strong family history of ovarian or breast cancer constitutes the most important risk
factor for ovarian cancer and this can be traced to an inherited mutation in one of two
genes, BRCA1 and BRCA2, which account for approximately 10% of all ovarian
cancers (16). In addition, increased ovarian cancer risk is associated also with hereditary
nonpolyposis colorectal cancer (HNPCC, also known as Lynch II) syndrome with
inherited mutations in DNA mismatch repair genes, primarily hMSH2 and hMLH1 (16).
In addition to genetic factors, aging is a clear risk factor for ovarian cancer, since the
incidence increases with age (17). In support of the incessant ovulation hypothesis,
factors reducing the number of lifetime ovulations have been associated with a reduced
risk of epithelial ovarian cancer. These include the number of pregnancies, oral
contraceptive use, breastfeeding (17, 18), and possibly late age at menarche as well as
an early age at menopause (19). In addition, tubal ligation and hysterectomy have been
associated with reduction of ovarian cancer risk (17, 18, 20). Infertility itself may be a
significant risk for ovarian cancer development (21, 22), but, at present, there is no
convincing data of an increased risk associated with infertility treatment (23).
Postmenopausal hormone replacement therapy has been suggested to associate with
increased ovarian cancer risk, although the data on association between combined
hormone replacement therapy and ovarian cancer are not entirely consistent (24-27).
Furthermore, in particular long-duration use of unopposed estrogen has been associated
with ovarian cancer risk in recent prospective studies (25, 28).
   Epithelial ovarian cancers appear to arise from ovarian surface epithelial cells via one
of at least two pathways: Type I tumours by slow development of precursor lesions,
from an inclusion cyst to a benign adenoma or cystadenoma of low malignant potential
through to metastatic adenocarcinoma, and type II tumours arising spontaneously and
aggressively from the surface epithelium or inclusion cysts without any precursor
lesions (29-31). The different histological types of epithelial ovarian cancer are
associated with different molecular genetic alterations and pathways of development
(Figure 1) (29-31). Low- and high-grade serous carcinomas most probably arise via
18
different pathways, the former progressing along an adenoma-borderline tumour-
carcinoma sequence and being characterised by KRAS or BRAF mutations, and the
latter appearing to arise de novo from morphologically normal or dysplastic epithelium
within inclusion cysts or on the surface of the ovary involving mutations of p53 and
BRCA1 and/or BRCA2 dysfunction (29-31). High-grade endometrioid ovarian
carcinomas involve molecular genetic alterations similar to high-grade serous
carcinomas and are probably closely related, whereas low-grade endometrioid
carcinomas display mutations in CTNNB1 (the gene encoding ?-catenin) and PTEN as
well as microsatellite instability (MI), and probably originate from ovarian
endometriosis or from endometrioid borderline tumours (31). Mucinous carcinomas
exhibit mutations in KRAS and seem to arise via an adenoma-borderline tumour-
carcinoma sequence (29-31). Furthermore, clear cell carcinomas probably have their
origin in ovarian endometriosis and possess mutations of TGFbetaR2, overexpression of
HNF-1beta, abnormalities of BRCA1 and/or BRCA2, and microsatellite instability. The
molecular changes present in transitional-cell carcinomas of the ovary remain largely
unknown (29, 31), and malignant mixed mesodermal tumours as well as
undifferentiated carcinoma have been designated as type II tumours (29).
19
   p53              KRAS                          KRAS                     CTNNB1                  TGFbetaR2
   BRCA1/2                BRAF                                                            PTEN                     HNF-1beta
                                                                                                              MI                BRCA1/2
               MI
Figure 1. Model of epithelial ovarian cancer development and molecular alterations associated
with the different histological subtypes. Modified from Christie and Oehler 2006 (31).
The spread of epithelial ovarian cancer occurs mainly via three mechanisms: direct
extension into contiguous pelvic structures, dissemination of free cancer cells shed from
the ovary into the peritoneal cavity and their distribution by normally circulating
peritoneal fluid, and spread by the lymphatic system (32-34). In contrast, hematologic
spread of ovarian cancer is not a common mode of ovarian cancer extension (32, 33).
The lymphatics of the ovary drain into the external iliac, common iliac, hypogastric,
lateral sacral, para-aortic nodes, and occasionally, to the inguinal nodes (3). As a
consequence of these ways of dissemination, a common site for metastases is the
peritoneum, including the omentum and pelvic and abdominal viscera, with frequent
diaphragmatic and liver-surface as well as pulmonary and pleural involvement (3, 32,
35). The ovarian cancer is staged according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system (36) based on the width of the
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ovarian cancer spread (Table 1) determined by surgical, cytological, and
histopathological findings in laparotomy, and possibly modified by clinical and
radiological findings (3).
Table 1. Staging of ovarian cancer according to the International Federation of Gynecology and
Obstetrics (1988; Ref. (36)).
Stage I Ovarian cancer with growth limited to the ovaries
Ia growth limited to one ovary; no ascites present containing malignant cells.
No tumour on the external surface; capsule intact
Ib growth limited to both ovaries; no ascites present containing malignant cells.
No tumour on the external surfaces; capsules intact
Ic tumour either Stage Ia or Ib, but with tumour on surface of one or both ovaries,
or with capsule ruptured, or with ascites present containing malignant cells,
or with positive peritoneal washings
Stage II Ovarian cancer with growth involving one or both ovaries with pelvic extension
IIa extension and/or metastases to the uterus and/or tubes
IIb extension to other pelvic tissues
IIc tumour either stage IIa or stage IIb, but with tumour on surface of one or both ovaries,
or with capsule(s) ruptured, or with ascites present containing malignant cells,
or with positive peritoneal washings
Stage III Ovarian cancer with tumour involving one or both ovaries with peritoneal implants
outside the pelvis and/or positive retroperitoneal or inguinal nodes.
Superficial liver metastasis equals Stage III. Tumour is limited to the true pelvis but with
histologically proven malignant extension to small bowel or omentum
IIIa tumour grossly limited to the true pelvis with negative nodes, but with histologically
confirmed microscopic seeding of abdominal peritoneal surfaces
IIIb tumour involving one or both ovaries with histologically confirmed implants of
abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes are negative
IIIc abdominal implants greater than 2 cm in diameter and/or positive retroperitoneal
or inguinal nodes
Stage IV Ovarian cancer with growth involving one or both ovaries with distant metastases.
If pleural effusion is present, there must be positive cytology to allot a case to Stage IV.
Parenchymal liver metastasis equals Stage IV
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2.3. Diagnosis and management of epithelial ovarian cancer
Although a significant proportion of patients with ovarian cancer apparently are
symptomatic even months before diagnosis, the symptoms are unspecific e.g. abdominal
pain, abdominal swelling, bloating, gastrointestinal disturbances, urinary symptoms,
fatigue and malaise (37-39). The lack of clear pathognomonic symptoms contributes to
the difficulty of making a clinical diagnosis of ovarian cancer and to the resulting
diagnostic delay (37, 38), and thus the majority of the ovarian cancers are diagnosed at
an advanced stage (stage III or IV) (3). Currently, there is no effective screening
protocol with an acceptable level of sensitivity or specificity available for the general
population (40). A suspected diagnosis of ovarian cancer is confirmed after a complete
physical pelvic and rectovaginal examination including a transvaginal ultrasound
examination. The additional preoperative assessment includes family history, a chest x-
ray, and ultrasound examination and CT scan of the abdomen and pelvis. Tumour
markers studied should include CA-125 and also carcinoembryonic antigen (CEA),
alpha-feto-protein, ?-chorionic gonadotropin (?HCG) and lactate dehydrogenase (LDH)
in the sense of differential diagnostics. The histological diagnosis is usually confirmed
at the time of surgery with frozen section analysis (41).
   The management for the patient who has completed childbearing is a surgical
procedure: comprehensive staging of ovarian cancer and aggressive cytoreduction of
advanced disease (34). Comprehensive surgical staging is the most important factor in
determining the appropriate adjuvant management (41). The operation should include
total hysterectomy with bilateral salpingo-oophorectomy, infracolic omentectomy, para-
aortic and pelvic lymphadenectomy, careful examination, palpation and random and
focused biopsies of diaphragm and peritoneum, as well as cytologic evaluation of
ascites or washings (41). The primary aim of surgery is to achieve maximal
cytoreduction with no gross residual disease after primary surgery. After the primary
operation, only those patients with stage Ia or Ib, grade 1 cancers, except for those with
clear cell histology, can be followed without the need for adjuvant chemotherapy (34,
41). All other patients need to be considered for adjuvant chemotherapy, this most
commonly consisting of a combination of a taxane and platinum therapy (34, 41).
   However, despite this treatment up to 75% of advanced-disease patients eventually
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suffer a recurrence and succumb to the disease (42, 43). At the present, there is no
established treatment for recurrent ovarian cancer, and the major influencing criterion is
platinum sensitivity, i.e. if the recurrence occurs within (platinum-resistant) or more
than 6 months (platinum-sensitive) after completion of primary platinum-based
chemotherapy. Active agents in the treatment of recurrent ovarian cancer include
docetaxel, topotecan, liposomal doxorubicin, etoposide, gemcitabine, paclitaxel,
carboplatin, cisplatin, and vinorelbine, all of which have been shown to have similar
response rates, ranging from 10-20% in platinum-resistant and 20-35% in platinum-
sensitive patients (34). Patients experiencing a recurrence more than 6 months after
primary therapy can be rechallenged with platinum-based chemotherapy, usually in
combination with paclitaxel, whereas other agents are considered for second recurrence
or platinum insensitivity (34). In addition, expectations of toxicity and impact on
patient's life quality contribute to the choice of second- or third-line chemotherapy.
Surgical reassessment by nature of a "second look" is rarely indicated (34, 41).
2.4. Clinicopathological prognostic factors in epithelial ovarian cancer
The most consistent prognostic factors observed in different studies are stage and post-
operative residual disease (44-46). In addition, although less often, also age at diagnosis,
histological grade and histological subtype have independently predicted survival in
some studies (44-46). Potential prognostic importance has been suggested also for
several molecular markers, but none have been conclusively shown to be of independent
prognostic significance and require clarification.
2.4.1. Age
The median age at diagnosis of ovarian cancer has been reported as being 63 years in
USA during the period 2000-2003 (47). The incidence of ovarian cancer increases with
advancing age, and higher proportions of the disease are seen in patients aged 50-69
years, with only 11% of patients being diagnosed younger than 40 years (3). The age of
the patient has been shown to be an independent predictor of survival in several studies
(5, 45, 48-52). The poor survival in the elderly could be due to high probability of being
diagnosed at an advanced stage (3, 53), or perhaps less aggressive treatment is used in
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the elderly than for younger women (48, 54-56), possibly at least partly because of co-
morbidity (57, 58).
2.4.2. Stage
Survival rates between the FIGO stages differ from each other, with overall survival
rates at 5 years of 89.3-78.2% for stage Ia-c, 79.2-68.2% for stage IIa-c, 49.2-28.9% for
stage IIIa-c, and only 13.4% for stage IV according to the FIGO annual report (3). The
FIGO stage is found to predict prognosis more consistently than many of the other
factors (44-46) and represents the basic criterion for selecting patients for different
treatment strategies emphasising the need for accurate surgical staging (41, 59).
Understaging of the disease has been observed in up to 30% of the patients (60-62).
Systemic aortic and pelvic lymphadenectomy has been shown to detect a higher
proportion of patients with metastatic lymph nodes as compared with lymph node
sampling (63), and the thoroughness of the staging has been proposed as being a
determinant of survival of early-stage ovarian cancer patients (64-66). Under these
circumstances, it is unfortunate that a significant number of patients with an apparent
early-stage ovarian cancer are still not staged according to the recommended surgical
protocol (64, 67).
2.4.3. Primary surgery
The amount of residual disease after primary cytoreductive surgery is one of the key
prognostic factors in ovarian cancer. Since this was described by Griffiths and
colleagues in 1970's (68), a large number of studies have shown the survival benefit of
primary optimal cytoreduction (44-46, 52, 69-71). The definition of "optimally resected
disease" is not consistent, but a residual tumour of less than 1 cm in maximal diameter
constitutes optimal cytoreduction according to The Gynecological Oncology Group
(72). However, patients in whom tumours are primarily debulked to no gross residual
disease derive the greatest survival benefit (3, 71, 73, 74) and it has been recommended
that optimal debulking surgery should be defined as no visibly residual tumour load (74,
75).
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2.4.4. Histological subtype
Epithelial ovarian tumours, which constitute the majority (90%) of malignant ovarian
tumours, are further classified as serous, mucinous, endometrioid, clear cell, transitional
cell, squamous cell, mixed epithelial, undifferentiated and unclassified histological
subtypes according to the World Health Organization (WHO) (Table 2) (76). The most
frequent subtype is a serous neoplasm, followed by endometrioid, mucinous, clear cell,
undifferentiated, and mixed epithelial subtypes (Table 2). Serous carcinoma is
predominantly found in advanced stages of the disease, peaking at stage III, whereas
clear cell, endometrioid and mucinous carcinomas tend to remain more frequently
confined to the ovary or pelvis (stages I-II). Among the six most common histological
subtypes, the overall survival rate at five years is poorest for the serous (37%) and
undifferentiated (37%) histological subtypes, while mucinous tumours are associated
with the most favourable prognosis (63%) especially at early stages (88%) (3). In
addition, there are conflicting data on the behaviour of clear cell carcinoma of the ovary.
In some studies, the prognosis appears to be similar to that of other ovarian carcinomas
(77, 78), whereas in other studies, clear cell subtype in comparison to serous and other
non-clear-cell epithelial ovarian carcinomas, has been suggested to exhibit a poor
prognosis at advanced stages (79-81) with insensitivity to platinum-based chemotherapy
(80-83). However, the significance of histological subtype as an independent predictor
of prognosis has remained controversial in epithelial ovarian cancer (44-46, 50, 70, 73,
84).
Table 2. Histological classification of epithelial ovarian cancers (modified from WHO 2003
(76), Heintz et al. 2003 (3), Ricciardelli and Rodgers 2006 (85), Kashimura et al. 1989 (86)).
Histological subtype Frequency Overall survival rate at 5 years
Serous adenocarcinoma 30-70% 37%
Mucinous adenocarcinoma 5-20% 63%
Endometrioid adenocarcinoma 10-20% 60%
Clear cell adenocarcinoma 3-10% 59%
Transitional cell carcinoma (TCC)/
Malignant Brenner tumour
rare 35% for TCC
Squamous cell carcinoma rare 28%
Mixed epithelial 0.5-4% 57%
Undifferentiated carcinoma 4-7% 6-37%
Unclassified adenocarcinoma rare not yet known
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2.4.5. Histological grade
There is no universally accepted grading system for epithelial ovarian carcinoma. The
most widely utilised grading systems are those of the FIGO (87) and the WHO (76, 88),
based mainly on architectural structures of the tumours, although not included in the
ovarian cancer staging system of either FIGO (36) or WHO (76). In Finland, a three-
class grading system based on architecture and nuclear atypia of the tumour has been
recommended by the Finnish division of the International Academy of Pathology (89).
The overall survival rate at five years has been reported to be 49-86% for well-
differentiated (grade 1) tumours, 26-78% for moderately differentiated (grade 2)
tumours, and 27-66% for poorly differentiated (grade 3) tumours (3). Histological
grading appears to have prognostic value in epithelial ovarian cancer, particularly for
early-stage disease (44, 65, 90, 91). However, its independent contribution has not been
firmly established (44-46, 73), although grading can have important implications for
therapeutic decisions, in particular in FIGO stage I (41). Assessment of grading's
contribution to prognosis is hampered by interobserver variability between pathologists,
lack of standardisation of grading schemes, and differences in the treatment protocols
(45, 46, 92-94).
2.4.6. Other prognostic factors
2.4.6.1. CA-125
CA-125 is a mucin (95) with a widespread distribution in human tissues and present to
varying degrees in the serum of patients with a variety of tumours. The CA-125
concentration is most consistently elevated in epithelial ovarian cancer, but CA-125
levels are elevated also in multiple gynecological and non-gynecological benign
diseases as well as in many other cancers e.g. cancers of the lung, breast, endometrium,
cervix, fallobian tube and gastrointestinal tract (96). Approximately 50% of the patients
with stage I ovarian cancer and 90% of those with the disease disseminated outside the
ovary have elevated concentrations of CA-125 in their sera (97), and the frequency of
positivity is greater in patients with nonmucinous tumours (97, 98). In clinical practice,
measurement of CA-125 may aid in differentiation between benign and malignant
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pelvic masses in postmenopausal women (96), whereas CA-125 is not suitable for
ovarian cancer screening as a single marker due to its limited sensitivity and specificity
(40). CA-125 has been shown to be useful in measuring the response to initial
chemotherapy since an indication for cessation or continuation of treatment can be
based on trends in CA-125 levels. In addition, it has been claimed that CA-125 can
provide a short lead-time for the detection of relapsed ovarian cancer before clinical
progression of disease, though the clinical value of this is less clear (73, 96). Both
absolute levels before therapy (99-103) and half-life (104-106) of CA-125 have been
shown in several publications to be independent prognostic indicators.
2.4.6.2. Ploidy
Aneuploidy is found in about 45-50% of stage I (107, 108) and in about 75% of stage
III-IV (108, 109) ovarian carcinomas. In contrast to the subjectivity of histological
grading and typing of ovarian cancer, ploidy determination offers the advantage of
being an objective and reproducible measurement and therefore has attracted great
attention in prognostic studies, although some with rather small materials (44). Tumour
aneuploidy has been clearly demonstrated to be an independent adverse prognostic
factor in both early- and advanced-stage epithelial ovarian cancer in several multivariate
studies with more than 100 patients included (107, 110-115), although also differing
results exist (116-122). Additionally, tumour ploidy has been suggested to be of
assistance in selecting patients with early ovarian cancer for adjuvant treatment after
surgery (111).
2.4.6.3. p53
p53 is a tumour suppressor gene, which is located on chromosome 17 (123) and plays a
role in both cell proliferation and apoptosis (124). p53 is inactivated in about half of
human cancers through mutations in the gene, and disruption of the p53 tumour
suppressor pathway is thought to contribute to the malignant phenotype. A mutation of
the p53 gene is the most common genetic alteration in ovarian cancer, with mutations
being present in approximately 50% of advanced-stage and in 10-20% of early-stage
ovarian carcinomas. In addition, mutations of the p53 gene have been observed also in
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borderline ovarian tumours, although not so frequently as in malignant tumours (123,
124). Especially, mutations of the p53 gene have been found to be common in high-
grade as opposed to low-grade ovarian serous carcinomas, and are thought to provide
evidence supporting the dualistic tumour progression model for ovarian carcinoma
development (29, 30). Due to the longer half-life of the mutant p53 protein, it
accumulates in the nucleus and this permits the immunohistochemical detection of the
mutant protein (125), although not entire extensively (126, 127). The p53 gene is one of
the most widely studied genes in relation to the prognosis of ovarian cancer. p53
expression has been reported to have independent prognostic value in some multivariate
studies (128-137) also in one prospective study setting (138), but not in others (139-
150) probably partly due to the marked methodological divergencies between the
studies.
2.5. Prognostic value of biological factors in epithelial ovarian cancer
2.5.1. Extracellular matrix and cell adhesion related factors
The extracellular matrix is a highly organised molecular network comprising a variety
of collagen superfamily and non-collagenous molecules such as glycoproteins,
proteoglycans, and hyaluronan (85). This delicate composition is constantly interacting
with the adjacent parenchymal cells, modulating the functional activity of these cells as
well as undertaking the continuous remodelling of the extracellular matrix structure and
composition during many physiological and pathological processes including normal
development, inflammation, wound healing and tumour development (85, 151).
   Proteoglycans are molecules characterised by the presence of long, unbranched, high
molecular weight side chains, called glycosaminoglycans (GAGs) that are covalently
attached to a core protein and include chondroitin, dermatan, heparin, and keratan
sulphate. Proteoglycans include commonly more than one type of GAG chains and can
be classified as heparin sulphate proteoglycans, lecticans with side chains consisting
mainly of chondroitin sulphate, and small leucine-rich proteoglycans with
predominantly chondroitin/dermatan sulphate or keratan sulphate side chains. These so-
called lecticans, also known as hyalectans or large aggregating proteoglycans, include
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aggrecan, versican, neurocan and brevican (85, 152). Proteoglycans can interact with
other extracellular matrix molecules and regulate a spectrum of cellular functions
including cell adhesion, signalling, migration, proliferation and differentiation (152).
Several cytokines, including transforming growth factor ?, platelet derived growth
factors and epidermal growth factor, seem to co-operatively regulate proteoglycan
levels (153).
   Cell adhesion to the adjacent structures is essential for the formation as well as the
maintenance of cellular and tissue integrity. Cell adhesion regulates many important
cellular processes including motility, growth, differentiation, and survival (154). Cells
adhere either directly to other cells or to the extracellular matrix. The types of cell-cell
adhesion in epithelial cell sheets consist of tight-, adherens- and gap-junctions. The
different junctions are built up of a transmembrane protein connected to a number of
intracellular proteins, which in turn connect to the cytoskeleton thus stabilising the
complex (155). The most common type of cell-cell adhesion, adherens junctions, are
made up of the cadherin-catenin complex (154).
   Cell adhesion receptors can be divided into five groups i.e. 1) the integrin family
mediating both cell-cell and cell-extracellular matrix adhesion, 2) the cadherin family,
3) the selectin family and 4) the immunoglobulin family mediating cell-cell adhesion,
and 5) other transmembrane proteoglycans, such as CD44, mediating cell-extracellular
matrix adhesion (156). Seamless co-ordination between these molecules is essential for
tissue integrity and morphogenesis (157). In addition to their structural role, cell
adhesion molecules function also by modulating intracellular signalling pathways in
response to extracellular conditions and in that way they regulate gene expression, cell
adhesion, migration, proliferation, death and differentiation status (156). Decreased
adhesion and aberrant adhesion-mediated signalling are typical of malignant
transformation, contributing to enhanced migration, proliferation, invasion and
metastasis of tumour cells (154).
2.5.1.1. Hyaluronan and CD44
Hyaluronan is a unique glycosaminoglycan that forms a major component of the
extracellular matrix. It is composed of repeats of disaccharides of glucuronic acid and
29
N-acetylglucosamine. The hyaluronan chain extrudes through the plasma membrane
onto the cell surface or into the extracellular matrix after its synthesis at the inner
surface of the plasma membrane by one of three hyaluronan synthases (HAS1, -2, or -3)
(158, 159). Hyaluronan has a remarkable ability to retain water, leading to an important
role in tissue homeostasis and biomechanical integrity. Hyaluronan also forms a
template for interactions with proteoglycans (Figure 2) and other extracellular
macromolecules such as versican, aggrecan and other hyaladherins, that is important in
the assembly of extracellular and pericellular matrices. This modulation of extracellular
space by hyaluronan contributes to the genesis of a favourable environment for tumour
cell division and migration (160). In addition, hyaluronan can influence cell behaviour
by interacting directly with the cell surface either by binding to cell surface receptors,
such as CD44 and receptor for hyaluronic acid mediated motility (RHAMM), or by
sustained attachment to hyaluronan synthase. This interaction leads to signal
transduction and cytoskeletal rearrangements that regulate cell growth, survival and
motility (161). Furthermore, hyaluronan may promote tumour progression also by
enhancement of angiogenesis (162-164).
Figure 2. The structural demonstration of E-cadherin-catenin complex and binding of
hyaluronan to CD44 and proteoglycans (versican) in peri- and extracellular matrix assembly.
Modified from Wijnhoven et al. 2000 (165) and Toole 2004 (161).
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Increased hyaluronan expression has been correlated with increased invasiveness of
cancer cells in vitro (166), and high levels of stromal hyaluronan have been associated
with poor survival in several cancers, for example ovarian (167), breast (168), prostate
(169, 170), and non-small cell lung (171) adenocarcinomas. Additionally, cancer cell-
associated hyaluronan accumulation has been associated with poor outcome in the
patients with breast (168) and colorectal (172) carcinomas, and also elevated levels of
the enzymes that cleave hyaluronan, namely hyaluronidases (usually HYAL1), have
been found in some malignant tumours (164, 173) and might promote tumour
progression through the stimulative effects of hyaluronan breakdown products on
angiogenesis (163, 174).
   CD44 is a transmembrane protein that is encoded by a single gene located on human
chromosome 11 and which exists as a standard isoform (CD44s) as well as several
CD44 variant isoforms produced through alternative splicing (175). In addition to
alternative splicing, CD44 function can be modulated also by post-translational
modifications such as phosphorylation and glycosylation (176). CD44 binds hyaluronan
(177) (Figure 2), and interactions between CD44 and hyaluronan have been suggested
to affect cell adhesion (178), migration (178, 179), growth (180) and peritoneal
implantation of ovarian cancer cells (181, 182). Expression of CD44 variants is
associated with clinically aggressive behaviour in some human tumours (183, 184).
Studies investigating CD44 expression and survival in ovarian cancer have reported
contradictory results. Some studies have demonstrated that high CD44 expression in
primary tumours is associated with poor (185-188) or improved (189-192) outcome,
while others have found no association between CD44 and survival (193-199).
2.5.1.2. Versican
Versican is a member of the family of large aggregating proteoglycans also known as
hyalectans or lecticans. It is composed of a core protein with chondroitin sulfate
glycosaminoglycans attached to the core (151). Versican is encoded by a single gene
localised on chromosome 5q12-14 in the human genome (200), and four versican
isoforms resulting from alternative splicing processes have been identified: the full-
length isoform V0 and smaller isoforms V1, V2, V3 with differences in the central
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portion of the core proteins. In versican V0, two chondroitin carrying segments, GAG-?
and GAG-?, are present, whereas the smaller V1 and V2 isoforms lack the GAG-? or
the GAG-? domain, respectively (201, 202), and the GAG carrying modules are both
deleted from the V3 isoform (203). All versican splice forms include globular domains
at the amino terminus (G1) and carboxyl terminus (G3). The G1 domain binds
hyaluronan with a high affinity (204), and the G3 domain consists of a set of lectin-,
epidermal growth factor- and complement binding protein-like subdomains (205, 206).
   In normal tissues, versican is found in connective tissues, most smooth muscle tissues,
veins and arteries, cartilage, neural tissue, glandular epithelia, and skin (207). Versican
interacts with its binding partners through its N- and C-terminal globular regions as well
as its central GAG-binding region. It can bind to extracellular matrix components such
as hyaluronan, type I collagen, tenascin-R, fibulin-1 and -2, fibrillin-1, fibronectin and
chemokines. It also binds to the cell surface proteins CD44, P- and L-selectin, integrin
?1, epidermal growth factor receptor, and P-selectin glycoprotein ligand-1 (208).
Versican is one of the main components of the extracellular matrix where it participates
in forming a loose and hydrated matrix (Figure 2). Since it undergoes direct or indirect
interactions with cells and molecules, versican is able to regulate cell adhesion and
survival, cell proliferation, cell migration, and extracellular matrix assembly (209).
   Versican has been found in many malignancies, including breast (210, 211),
endometrial (212), prostate (213) and colon (214) carcinoma, being localised mainly in
the peritumoural stromal tissue but also cancer cell-associated expression has been
reported in melanoma (215) as well as in prostate (216), endometrial (212), pharyngeal
squamous cell (217) and non-small cell lung (218) cancers. Versican has been suggested
to cause decreased cell-cell and cell-matrix adhesion, thus facilitating local cancer cell
invasion and the formation of metastases (209). Elevated levels of versican have been
associated with poor outcome in many cancers including breast (211, 219), endometrial
(212), prostate (213) and oral squamous cell (220) carcinomas. However, the
distribution and prognostic value of versican has not yet been elucidated in epithelial
ovarian cancer.
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2.5.1.3. E-cadherin-catenin complex
In general, the E-cadherin-catenin complex is important for maintaining tissue
architecture, and this complex can limit cell movement and proliferation. The major
epithelial cell cadherin, E-cadherin, binds via its cytoplasmic domain to ?- or ?-catenin
(plakoglobin), which are linked to the actin cytoskeleton via ?-catenin (154). E-cadherin
can bind also p120-catenin, which contributes to stabilisation of cadherin-catenin
complex (221) (Figure 2). These interactions are critical for the establishment of stable
and functional adherens junctions. The disruption of normal cell-cell adhesion by the
downregulation of the cadherin or catenin expression may lead to enhanced cell
migration and proliferation as well as invasion and metastasis of tumour cells (154).
Indeed, the loss of E-cadherin expression has been associated with the transition from
adenoma to invasive pancreatic carcinoma and the acquisition of a metastatic capability
(222), furthermore experiments where cadherin expression has been restored have
confirmed E-cadherin as an invasion suppressor (223). In addition, altered expression
and localisation of the catenins can play an important role in tumourigenesis (224, 225).
   In addition to providing a link between cells, the cadherin-catenin complex can
influence various signalling pathways (154). Accordingly, ?-catenin plays a dual role in
the cells: in addition to its structural role in the complex, ?-catenin can act as a
transcription cofactor in the nucleus by interacting with the LEF/TCF (lymphoid
enhancer factor/T-cell factor) DNA binding proteins. ?-catenin-mediated transcription is
activated by the Wnt pathway, the activation of which results in the inhibition of ?-
catenin degradation, its nuclear accumulation and transcriptional activation of LEF/TCF
target genes, such as Cyclin D1 and Myc (Figure 3). Translocation of ?-catenin into the
nucleus might be required to induce the expression of genes that promote cell
proliferation and invasion (154, 226).
33
Figure 3. Representation of the central role of ?-catenin in Wnt signalling. ?-catenin can exist
in a cadherin-bound form, taking part in the regulation of adhesion, or it can be sequestered in a
complex with axin, APC, and GSK-3?, enabling its degradation by ?-TrCP. Activation of Wnt
pathway or other abnormalities in this degradation pathway results in the entry of ?-catenin to
the nucleus, where it can bind to transcription factors (LEF/TCF) and stimulate transcription of
target genes. Modified from Wijnhoven et al. 2000 (165) and Nelson and Nusse 2004 (226).
In accordance with the mesodermal origin of ovarian surface epithelium and its less
firmly determined differentiation compared to many other epithelia (227), the E-
cadherin expression, an epithelial characteristic, is rarely detected in normal ovarian
surface epithelium (228, 229). However, E-cadherin expression has been found to
increase in metaplastic ovarian surface epithelium, benign and neoplastic ovarian
tumours (228-230) as the cells become increasingly committed to epithelial phenotypes.
During the progression of ovarian cancer, the tumour cells once again lose their
differentiation when they undergo an epithelial-mesenchymal transition (231), and
accordingly, a decrease in E-cadherin expression is observed in poorly differentiated
ovarian cancers (228, 228, 232, 233), most probably because of silencing the E-cadherin
gene via methylation of its promoter (233) or by transcriptional repressors such as Snail
and Slug (234), whereas somatic mutations of E-cadherin gene have been reported to be
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rare in ovarian cancer (235). Consequently, in ovarian cancer E-cadherin has been
suggested to contribute to neoplastic progression in the earliest stages but to act as a late
stage tumour suppressor (236, 237).
   In contrast to E-cadherin, the expression of catenins can be observed in normal
ovarian surface epithelium (228, 238), possibly in association with cadherins other than
E-cadherin (238), whereas the expression is found to be reduced in ovarian cancer
(228). Furthermore, the reduced expression of ?-, ?- or ?-catenins has been found in
ovarian cancers with adverse clinicopathologic features (239, 240). The prognostic
significance of E-cadherin-catenin complex is still unclear, but aberrant expression of E-
cadherin has been shown to associate with poor survival in many malignancies (241-
243). Additionally, reduced expressions of ?-, ?- and ?-catenins have been reported to
predict unfavourable prognosis in many carcinomas (241, 244-247). Previous studies on
E-cadherin-catenin complex in ovarian cancer are quite limited and have left the
prognostic role of this complex unclear (186, 232, 248-254).
2.5.1.4. Other factors related to cell adhesion
Integrins are cell surface glycoprotein receptors that mediate cell adhesion to
extracellular matrix, and also cell-cell binding to other adhesion molecules. They are
composed of a heterodimer of two noncovalently associated transmembrane ?- and ?-
subunits, that can combine to give at least 24 integrin dimers, and the particular
combinations of the ?- and ?-chains define the specific repertoire of ligands (156). The
cytoplasmic tails of the ?- and ?-chains interact with cytoskeletal proteins and activate
signal transduction pathways to regulate cell proliferation, apoptosis, gene expression,
differentiation, and cell migration (255). Cells can gain more potential to invade and
metastasise as a result of the altered expression, function, and activation of integrins,
and several integrins have been also indirectly linked to tumour development via their
role in regulating angiogenesis (256). The relationships between expression of some
integrins and clinical stage, tumour progression, and prognosis have been reported e.g.
in cases of colon and breast cancers (156). In addition to the proposed role in mediating
the adhesion of ovarian carcinoma cells to mesothelial cells (182), an association of
integrin expression with survival has been claimed also for ovarian cancer (257, 258).
35
   Selectins are a small family of calcium-dependent transmembrane glycoproteins
including E-, P-, and L-selectins, that mediate heterotypic cell-cell adhesion. E- and L-
selectins may contribute to tumour growth by increasing angiogenesis or by activation
of selectin-dependent signal transduction pathways, which can regulate cancer cell
proliferation, migration, and survival (156). E- and P-selectins have been reported to be
absent on the ovarian tumour cells in vitro (259), whereas an increased serum
concentration of E-selectin in ovarian cancer has been reported (260). The significance
of this observation, as well as the prognostic significance of selectins in ovarian cancer,
remains unknown.
   The immunoglobulin superfamily consists of adhesion molecules that mediate cell-
cell adhesion and contain extracellular immunoglobulin domains. These molecules
mediate interactions of endothelium with leukocytes and cancer cells, and several
members of this family have been linked to cancer progression. For example, Ep-CAM,
transmembrane glycoprotein expressed on the surface of most human epithelial cells,
may negatively regulate cadherin-mediated adhesion and has been associated with poor
prognosis in breast, colorectal, prostate (156) and ovarian cancers (261). Other members
of the immunoglobulin superfamily, such as intercellular adhesion molecule 1 (ICAM-
1) (262) and extracellular matrix metalloproteinase inducer (EMMPRIN) (263), have
been linked to survival of ovarian cancer patients as well.
2.5.2. Angiogenesis-related factors
Angiogenesis, the growth of new capillary blood vessels is essential for tumour growth
and metastasis, since neovascularisation of a tumour is necessary if the tumour is to
expand beyond 2 mm3 (264). Normally the tissue microenvironment maintains a
delicate balance between pro- and anti-angiogenic growth factors (265). However,
depending on environmental factors such as hypoxia, the balance can be shifted in
favour of angiogenesis by upregulating the levels of proangiogenic factors or by
reducing those of angiogenesis inhibitors, such as thrombospondin-1 (TSP-1),
angiostatin and endostatin. The major angiogenic factors include VEGF, fibroblast
growth factor (FGF), interleukin-8 and angiopoietins (266). In addition, several other
factors have been related to the regulation of angiogenesis. For example, hyaluronan
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(163) and versican (267) have been claimed to modify angiogenesis.
2.5.2.1. Inducible nitric oxide synthase
Nitric oxide (NO) is a multifunctional gaseous compound and a short-lived highly
reactive molecule that regulates many physiological and pathophysiological processes,
such as vascular functions, including angiogenesis (268). NO has been shown to have
both promoting and inhibiting effects on tumour progression and metastasis. These
effects seem to be context-dependent and can be influenced by the concentration and
duration of NO exposure and cellular sensitivity to NO (269).
   NO is produced from L-arginine in the presence of cofactors by three different
isoforms of NO synthases (NOS): neuronal NOS (nNOS, NOS1), inducible NOS
(iNOS, NOS2) and endothelial NOS (eNOS, NOS3), each encoded by distinct genes
sharing a similar genomic structure. iNOS gene is located on chromosome 17, and like
other isoforms, iNOS is composed of a amino-terminal oxygenase domain containing
binding sites for haem, tetrahydrobiopterine (BH4) and L-arginine, linked by a
calmodulin-recognition site to a carboxy-terminal reductase domain containing binding
sites for flavin-adenine dinucleotide (FAD), flavin mononucleotide (FMN) and
nicotinamide adenine dinucleotide phosphate (NADPH) (270). nNOS and eNOS are
expressed constitutively and their activity is dependent on the level of calcium, whereas
calcium-independent iNOS is not present in resting cells but its expression in many cells
such as tumour cells, tumour-associated stromal fibroblasts and immune cells can be
induced by inflammatory cytokines, endotoxin, hypoxia and oxidative stress to produce
higher levels of NO than either nNOS or eNOS (269).
   Expression of iNOS has been detected in many human tumours, such as breast (271),
colorectal (272), prostate (273) and gynecological (274, 275), including also ovarian
(276-279) tumours. In many tumours, the expression level of iNOS is increased
compared to the corresponding normal tissues though there are some exceptions (280,
281). iNOS has been reported to have prognostic value, although again contradictory
results have been reported with different cancers (272, 273, 275, 282). In this respect,
the prognostic significance of iNOS has remained controversial in ovarian carcinoma
(278, 279).
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2.5.2.2. Microvessel counting and the Chalkley method in the assessment of tumour
vascularisation
Tumour angiogenesis and its prognostic importance in different carcinomas have been
commonly assessed by the tumour microvessel density evaluation technique introduced
by Weidner et al. (283), based on counting the number of stained microvessels on areas
of most intense tumour vascularisation. For this purpose to mark the endothelium,
antibodies to CD34 (284-290), CD31 (291-293), von Willebrand factor (Factor VIII)
(294-297) and Ulex (298) have been used in prognostic ovarian cancer studies. CD34 is
a cell surface protein that is selectively expressed by human hematopoietic progenitor
cells and vascular endothelial cells (299, 300), and it has been shown to identify tumour
vessels also in the solid cancers of the ovary (301) in a more consistent way than CD31
or Factor VIII (302). In addition, recently the Chalkley count was introduced, based on
the Chalkley eyepiece graticule and the number of grid points that hit stained
microvessels, representing a relative area estimate rather than a true vessel count (303).
In an international consensus report this assay with CD34 immunostaining was
proposed to represent a standard method for angiogenesis quantification in solid tumour
sections (304). However, no previous studies on the Chalkley method and its prognostic
significance exist with respect to ovarian cancer. Ovarian cancer studies using the
microvessel density counting for angiogenesis determination have resulted in
conflicting claims about the prognostic significance of angiogenesis (284, 286, 288-294,
297, 298, 305-310). The studies published with multivariate survival analyses are
summarised in Table 3.
   Angiogenesis as evaluated by the Chalkley method and its prognostic significance
have been studied previously in other carcinomas, especially in breast cancer in which
the association of poor outcome of patients with increasing angiogenesis has been
shown (311-314), although a lack of associations has also been reported (315, 316). In
other tumours, the method has been shown to have prognostic significance (317, 318),
or to lack significance (319, 320), or its prognostic significance remains equivocal (311,
321-324) probably at least partly because of differences in the methodology.
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Table 3. Angiogenesis and prognosis in ovarian cancer; studies with multivariate
survival analyses.
Author (ref.) N* Material* Antibody Result
Hollingsworth et al.
1995 (305)
43 FIGO III-IV CD34 low average microvessel count
? improved disease-free survival
Obermair et al. 1999
(284)
63 FIGO I-III CD34 ns
Ogawa et al. 2002
(286)
105 CD34 high microvessel density
? better progression-free survival
Gadducci et al. 2006
(307)
101 FIGO III-IV CD34 high intratumoural microvessel density ?
better progression-free and overall survival
Chan et al. 2004
(308)
46 FIGO III-IV CD34 lower microvessel density
? worse survival
Lösch et al. 2004
(288)
80 CD34 ns
Raspollini et al. 2005
(306)
60 FIGO IIIc,
serous, grade 3
CD34 high microvessel density
? poor survival (relapse and death)
Solomon et al. 2006
(289)
118 FIGO III-IV,
serous, grade 2-3
CD34 low microvessel density
? improved survival
Ino et al. 2006
(290)
67 CD34 ns
Gasparini et al. 1996
(291)
60 FIGO III-IV CD31 ns
Nishida et al. 2004
(292)
80 CD31 ns
Goodheart et al. 2002
(293)
77 CD31 ns
Goodheart et al. 2005
(309)
77 FIGO I CD31 high microvessel count ? poor disease-
specific and recurrence-free survival in
FIGO Ic substage
Alvarez et al. 1999
(294)
85 vWF
(FVIII)
ns
Abulafia et al. 1997
(310)
42 vWF
(FVIII)
ns (in primary tumours; significant in
omental metastases)
Shen et al. 2000
(297)
64 vWF
(FVIII)
ns
van Diest et al. 1995
(298)
49 FIGO III-IV Ulex ns
ns=no significance
*in multivariate analysis
vWF=von Willebrand factor
FVIII=Factor VIII
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2.5.2.3. Other factors related to angiogenesis
2.5.2.3.1. Vascular endothelial growth factor
A number of growth factor receptor pathways promote tumour angiogenesis. One of the
major pathways involved in this process is the vascular endothelial growth factor
(VEGF) family of proteins and receptors. The VEGF family consists of VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor (PlGF), which have
specific binding affinities towards the VEGF receptors (VEGFR)-1, VEGFR-2 and
VEGFR-3 (325). VEGF-A, commonly referred to as VEGF, is a 45-kDa homodimeric
glycoprotein that undergoes alternative splicing to different isoforms with a diverse
range of angiogenic activities, whereas VEGF-C and VEGF-D play key roles in the
process of lymphangiogenesis but their contribution to tumour angiogenesis is unclear
(325).
   Activation of the VEGF/VEGF-receptor axis triggers multiple signalling networks
that result in endothelial cell survival, mitogenesis, migration, differentiation, and
mobilisation of endothelial progenitor cells from the bone marrow to distant sites of
neovascularisation. In addition, VEGF mediates vessel permeability, leading to
deposition of proteins in the interstitium and this facilitates angiogenesis (325). The
production of VEGF is regulated by the local oxygen concentration, i.e. hypoxia
stimulates VEGF production mainly through a stimulative effect of hypoxia inducible
factor (HIF) on VEGF gene transcription. However, the oxygen concentration is not the
only regulator of VEGF synthesis (326).
   Overexpression of VEGF in tumour tissues has been associated with tumour
progression and poor prognosis in a variety of solid tumours including colorectal (327-
329), breast (330-332) and prostate (333) carcinomas. The contradictory results from
ovarian cancer studies are based on small study materials, with some reports
demonstrating an association of VEGF overexpression and poor outcome (292, 297,
306, 309, 334-337) while others report a lack of any association (295, 296).
2.5.2.3.2. Placenta growth factor
Placenta growth factor (PlGF) belongs to the VEGF family and is expressed in placenta,
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heart, lung, thyroid gland and skeletal muscle. Four isoforms, PlGF-1-4, differing in
size and binding properties are produced through alternative splicing of the human PlGF
gene (338). Loss of PlGF has been shown to impair angiogenesis during ischaemia,
inflammation, wound healing and cancer (339). However, the role of PlGF in pathologic
angiogenesis has proved to be controversial. While PlGF has been claimed to enhance
tumour growth, endothelial cell survival and angiogenesis (339, 340), it has also been
reported to inhibit tumour angiogenesis and growth (341, 342).
   PlGF has been shown to be upregulated in breast, colorectal and gastric cancers
compared to the corresponding non-tumourous tissues, and PlGF expression is
correlated with aggressive features in the tumours and a poor prognosis in these cancers
(343-345). The data of the role of PlGF in ovarian cancer are scanty and indicate that
PlGF expression appears to be absent in ovarian tissues (346).
2.5.2.3.3. Hypoxia inducible factor-1?
Hypoxia inducible factor (HIF)-1 is a transcription factor composed of HIF-1? and HIF-
?? subunits. While the HIF-1? subunit is expressed constitutively and its activity is
controlled in an oxygen independent manner, the HIF-1? is a unique, O2-regulated
subunit that primarily determines HIF-1 activity (347, 348). HIF-1 is additionally
overexpressed by hypoxia independent pathways, such as those caused by mutations in
oncogenes or tumour-suppressor genes (349). The HIF-1? subunit is induced by cellular
hypoxia and maintained at low levels in most cells under normal oxygen tension (347,
348). Nuclear accumulation of HIF-1? under hypoxic conditions can transactivate more
than 60 target genes involved in many aspects of cancer biology including cell survival,
glucose metabolism, cell adhesion and angiogenesis to increase O2 availability or to
allow metabolic adaptation to O2 deprivation (349). These genes include those encoding
for erythropoietin, iNOS, VEGF, and many enzymes involved in glucose, iron, and
nucleotide metabolism (349).
   Overexpression of HIF-1? has been shown to occur in many tumour types compared
with the respective normal tissues, including ovarian cancer (350-352). Most cancers
overexpressing HIF-1? are associated with increased mortality. Adverse effects on
patient survival have been found in breast (353-356) and gynecological (357-360)
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cancers, whereas HIF-1? does not seem to play such an important prognostic role for
instance in colorectal cancer (361, 362). The independent prognostic significance of
HIF-1? remains unconfirmed also in ovarian cancer (363-365). The effect of HIF-1?
expression in individual cancers seems to be dependent on the specific cancer type as
well as the presence or absence of genetic alterations that affect the balance between
either pro- or anti-apoptotic effects.
2.5.2.3.4. Thrombospondin-1
The thrombospondin (TSP) family consists of five extracellular glycoproteins, TSP-1-5,
of which TSP-1 has functions in platelet aggregation, inflammatory response, cellular
adhesion and regulation of angiogenesis (366). The anti-angiogenic activity of TSP-1
has been shown to be mediated by inhibition of endothelial cell migration and induction
of endothelial cell apoptosis as well as by its inhibitory effect on VEGF via the
antagonism of VEGF-mediated survival, inhibition of VEGF mobilisation from
extracellular matrix, as well as directly binding to VEGF to promote its cellular
internalisation (367, 368). The regulation of TSP-1 is complex and modulated by
growth factors, tumour suppressor genes and oncogenes. The tumour suppressor gene
p53 has been shown to upregulate the TSP-1 gene expression at the transcriptional level,
with the loss of wild-type p53 expression leading to decreased TSP-1 expression (369),
whereas activation of oncogenes such as jun, src, and myc contributes to down-
regulation of TSP-1 gene expression (366, 367).
   TSP-1 expression has been shown to associate with better survival in colon (370) and
invasive cervical (371) carcinomas, whereas no relationship to patient outcome seems to
occur in endometrial (372), prostate (373, 374) and breast (375, 376) cancer. The
association of TSP-1 with patient outcome has not been clarified in ovarian cancer.
TSP-1 gene expression has been associated with the aggressive phenotype and poor
survival (377), but conversely more intense immunohistochemical expression of TSP-1
has been shown to associate with better survival in advanced stage ovarian cancer (378)
or to have no prognostic significance in early stage disease (309). Data from the
literature indicate that during tumour progression and prolonged exposure to a TSP-1
rich environment, tumour cells may develop resistance to its anti-angiogenic effects and
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increase the secretion of angiogenic factors such as VEGF to counterbalance the
inhibitory effects of TSP-1 (367, 379). In addition, different fragments of TSP-1 may
have varying degrees of angiogenesis-modulating properties and some may also possess
proangiogenic effects (380), which may explain some of the conflicting results from the
prognostic studies.
2.5.2.3.5. Platelet-derived growth factor
The platelet-derived growth factors (PDGFs) comprise a family of polypeptides, PDGF-
A, PDGF-B, PDGF-C, and PDGF-D, that form homo- or heterodimers. They exert their
cellular effects through two tyrosine kinase receptors, PDGFR-? and PDGFR-?,
resulting in cell migration, proliferation and survival (381). In addition to its important
role in embryonic development, PDGF overactivity has been related to many types of
pathological processes, including cancer development. PDGF ligand-receptor system
may function in autocrine stimulation of tumour growth, enhance tumour angiogenesis
through pericyte recruitment and affect drug delivery by taking part in interstitial fluid
pressure regulation (381).
   The expression of PDGF or its receptors has been associated with the metastatic
potential of different cancer cells (382-385), and positivity for PDGF-AA has claimed
to have a negative impact on the prognosis of advanced stage breast cancer patients
(386). Expression of different PDGF dimers has been reported also in ovarian cancer
(387-391). In addition, although PDGF receptors were initially suggested to be absent
(388, 392), there is now a growing body of evidence that these PDGF receptors exist in
ovarian cancer cells (389, 390, 393) and there they may have an autocrine effect on cell
proliferation (390). Furthermore, positivity for PDGFR-? has been associated with a
reduced survival in epithelial ovarian cancer (387).
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3. AIMS OF THE STUDY
The aim of the present study was to evaluate the expression and prognostic value of
novel molecular markers as well as their association with several conventional
clinicopathological factors in epithelial ovarian cancer. In addition, the purpose was to
increase current knowledge of the fundamentals of epithelial ovarian cancer biology
since this underlies the disease progression. The specific aims of the present study were:
1) To study the expression and prognostic value of versican as well as its association
with hyaluronan expression in epithelial ovarian cancer.
2) To investigate the expression pattern and prognostic significance of E-cadherin-
catenin complex in epithelial ovarian cancer.
3) To assess the expression and prognostic relevance of iNOS in epithelial ovarian
cancer
4) To evaluate the Chalkley method in the assessment of angiogenesis as well as its
prognostic value in epithelial ovarian cancer.
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4. MATERIAL AND METHODS
4.1. Study material
The present study material was selected from a consecutive series of 445 women
diagnosed and treated for ovarian malignancy in Kuopio University Hospital and
Jyväskylä Central Hospital, Finland, between 1976 and 1992, and followed-up until
January 2004 with the protocols valid at that time. The relevant clinical data were
collected from patients' files retrospectively. Patients with non-epithelial type cancers
(n=36), patients who were not operated on (n=35) or who were given any treatment
before operation (n=33) and usually represent patients with an extremely poor
prognosis, were excluded as were also cases with insufficient tumour material (n=36-42
in studies I-III). In addition, the study cohort in study IV was smaller compared to the
other studies and consisted of 175 randomly selected patients. Thus, altogether 310
patients (175 to 305 patients in separate studies) were left for analyses (Table 5).
   Tumour staging was re-evaluated from the patients' operative and histopathological
files and was based on the standards of the International Federation of Gynecology and
Obstetrics (FIGO) (36). Histological subtype and grade were re-evaluated according to
the WHO classification (394) previously (128, 395). Death certificates were collected
from the patients' files or obtained from the Finnish Cancer Registry. Patients who died
because of any post-operative complications (deaths within one month after the
operation) were not included in survival analyses. Tissue samples were fixed in 10%
formalin and embedded in paraffin. Each 5 µm-thick sample was stained with
haematoxylin and eosin.
4.2. Histochemistry of hyaluronan (I)
The biotinylated complex of hyaluronan-binding region of aggrecan and link protein
(bHABC) was prepared from bovine articular cartilage and tested for purity (396, 397).
The whole staining procedure of hyaluronan has been described in detail previously
(167, 396).
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4.3. Immunohistochemical stainings (I-IV)
The immunohistochemical stainings were performed according to the following
immunoperoxidase protocol, with modifications in antigen retrieval and primary
antibodies used (Table 4). Five-mm-thick paraffin-embedded tumour sections were
deparaffinised and rehydrated using xylene and graded alcohols. To achieve better
antigen retrieval, the sections were heated in a microwave oven in a citrate buffer (Tris-
HCL for ?-catenin (395)). Endogenous peroxidase activity was blocked by 5%
hydrogen peroxide treatment for 5 min, followed by washings with water for 2´5 min
and with PBS for 2x5 min. Nonspecific binding was blocked with 1.5% normal horse
serum in PBS at room temperature. The samples were incubated overnight at 4°C with
the primary antibody, and then for 35 min (30 min for iNOS and 45 min for E-cadherin)
with the biotinylated secondary antibody, preceded and followed by washings twice for
5 min with PBS. Then, the slides were incubated (for 45-50 min) in preformed avidin-
biotinylated peroxidase complex (ABC Vectastain Elite kit, Vector Laboratories,
Burlingame, CA, USA) and washed twice for 5 min with PBS. The colour was
developed with diaminobenzidine tetrahydrochloride (DAB) (Sigma, St. Louis, MO,
USA). The slides were counterstained with Mayer´s haematoxylin, washed, dehydrated,
cleared and mounted with DePex (BDH, Poole, UK). An ovarian cancer section
processed without the primary antibody served as a negative control in each staining
series. Skin samples showing intense staining for versican were used as positive
controls for versican staining in each batch. A known E-cadherin positive ovarian
cancer sample, a ?-catenin positive thyroid cancer sample, a ?-catenin positive lung
cancer sample, and an iNOS positive colorectal sample were used as external positive
controls in E-cadherin-catenin complex and iNOS stainings. For iNOS staining,
mononuclear inflammatory cells that had been stained in the cancerous stroma served as
internal positive controls. For CD34, hemangioma served as an external positive
control.
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Table 4. Summary of the antibodies used in the study.
Marker
(study
number)
Antibody Manufacturer Dilution Antigen
retrieval
Versican (I) anti-versican,
clone 2B1, monoclonal
Seikagaku Corporation,
Japan
1:1000 microwave +
citrate buffer
(pH 6.0)
E-cadherin (II) anti-E-cadherin,
clone HECD-1,
monoclonal
Zymed Laboratories Inc.,
South San Francisco, CA,
USA
1:100 microwave +
citrate buffer
(pH 8.0)
?-catenin
(Ref. (395))
anti-?-catenin,
clone 5, monoclonal
Transduction Laboratories,
Lexington, KY, USA
1:150 microwave +
Tris-HCL
(pH 9.7)
b-catenin (II) anti-beta-catenin,
clone 14, monoclonal
Transduction Laboratories,
Lexington, KY, USA
1:1000 microwave +
citrate buffer
(pH 6.0)
g-catenin (II) anti-gamma-catenin, clone
15, monoclonal
Transduction Laboratories,
Lexington, KY, USA
1:100 microwave +
citrate buffer
(pH 6.0)
CD44 (II)
(Ref. (189))
anti-CD44,
clone 2C5, monoclonal
R&D Systems,
Abingdon, UK
1:1200 microwave +
citrate buffer
(pH 6.0)
iNOS (III) anti-iNOS
monoclonal
Transduction Laboratories,
Lexington, Ky., USA
1:200 microwave +
citrate buffer
(pH 9.7)
CD34 (IV) anti-CD34, Anti-HPCA-1,
clone My10, monoclonal
Becton Dickinson
Immunocytometry Systems,
San Jose, CA, USA
1:200 microwave +
citrate buffer
(pH 6.0)
4.4. Evaluation of the stainings
All stainings were evaluated using a light microscope. The samples were analyzed by
two or three observers, who were unaware of the clinical data of the patients. In the case
of disagreement between the observers, the slides were reviewed and a consensus was
reached.
4.4.1. Versican (I)
All specimens were analysed by three observers (K.V., S.S., V.-M.K.) Versican
expression was observed in stromal area and also in cancer cells. The intensity of the
total peri- and intratumoural stromal versican in the whole section was evaluated and
graded into three categories: weak=1, moderate=2 and strong=3, using the intense
staining seen in dermis of skin samples as an external control for strong intensity. The
percentage of stroma with the strong versican intensity of the total peri- and
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intratumoural stromal area was evaluated and categorised into two groups: low (<15%),
or high (>15%), according to the median percentage value. The percentage of versican
positive tumour cells of all cancer cells in the section was also estimated, but for
statistical analyses, the tumours were grouped into two categories: versican negative or
positive. A tumour was considered positive if any cancer cell-associated versican signal
was observed.
4.4.2. Hyaluronan (I)
The hyaluronan staining was evaluated previously (167). Hyaluronan intensity in stroma
was categorised as: weak=1, moderate=2, strong=3 using the strongest staining of
hyaluronan in the peri- and intratumoural stroma as an internal positive control. The
grading of the strong stromal hyaluronan staining percentage of total peri- and
intratumoural stromal area was done using the 33rd and 66th percentiles in a frequency
distribution: low (<35%), moderate (35-75%), high (>75%) (167).
4.4.3. E-cadherin-catenin complex (II)
Immunostainings of E-cadherin, b- and g-catenins were analysed by three observers
(K.V., S.S., K.R.). The intensity of the staining of cancer cells was categorised into two
groups: weak or strong. Strong intensity was equal to the intensity of the cancer cell
membrane seen in the external positive controls, and weak staining corresponded to the
intensities between strong and negative. The staining pattern was considered continuous
when membranes around cancer cells showed an uninterrupted signal, whereas
uncontinuous staining included fragmentary membranous staining and also cytoplasmic
staining of cancer cells. The percentage area of tumour cells showing strong continuous
staining was analysed from the total tumour cell area and further categorised into two
groups according to the median percentage of the expression (5% for E-cadherin, b- and
g-catenins): reduced expression, when <5% of the tumour cells expressed strong
continuous membranous staining; and preserved expression, when >5% of the tumour
cells expressed strong continuous membranous staining. The presence of nuclear
staining was also analysed and directly graded into two categories: positive or negative.
Nuclear staining was considered positive if >5% of the tumour cell nuclei were positive.
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The ?-catenin staining was evaluated previously (395). The staining was located on the
cell membranes and classified into two groups: normal, when all tumour cells expressed
?-catenin homogenously, and reduced, when less than 100% of the tumour cells
expressed ?-catenin. The reduced ?-catenin expression was further categorised into two
groups: subnormal (30-99%), or exceedingly low (<30%) (395).
4.4.4. CD44 (II)
The CD44 staining was evaluated previously (167, 189). The expression of CD44 was
observed on the cell membranes, scored as a fraction of positive cancer cells in the
whole tumour cell area, and further categorised into two groups according to the median
percentage of the expression: low, when <10% of the tumour cells expressed CD44, and
high, when >10% of the tumour cells expressed CD44 (167, 189).
4.4.5. iNOS (III)
The samples were analysed by three observers (M.A., S.M., V.-M.K.). The expression
of iNOS was analysed as a percentage of positive cancer cells in the whole tumour cell
area and divided into two categories according to the 66th percentile in the frequency
distribution of the expression: low, when <70% and high, when >70% of the tumour
cells expressed iNOS. In addition, the intensity of iNOS was categorised into three
groups; 0 (negative), 1 (weak to moderate) or 2 (strong).
4.4.6. CD34 (IV)
Angiogenesis in ovarian cancer samples was evaluated by two observers (K.S. and
M.A.), using the Chalkley method in the assessment of tumour vascularisation. The
CD34-stained sections were scanned at low magnification (x12.5 ocular, x4 and x10
objective) for the most vascularised areas within the tumour section, and three areas
with the highest vascularity (hot spots) were chosen subjectively. A 25-point Chalkley
eyepiece graticule (Graticules, Pyser-SGI Limited, United Kingdom) was applied to
each hot spot at higher magnification (x12.5 ocular and x20 objective, corresponding to
an area of 0.322 mm2), and oriented to permit the maximum number of points to hit on
or within the immunohistochemically stained microvessels. The Chalkley count was
49
expressed as the mean value of the three counts for each tumour and further classified
into two groups according to the median value of Chalkley count: low <8, or high >8.
4.5. Statistical analyses
Statistical analyses were carried out using the SPSS for Windows computer programme
package (SPSS Inc., Chicago, IL, USA). The relationships between continuous
variables were tested using Spearman correlation coefficients and Wilcoxon tests. c2-
test was used to evaluate the interrelationships between categorised IHC variables and
their associations with the clinicopathological factors. The coefficient of variation (CV)
was used to analyse the reproducibility data from the Chalkley method, and
interobserver agreement for the intensity of the iNOS staining was evaluated by kappa
statistics. Univariate survival analyses were performed with the Kaplan-Meier method
(398), using the log-rank test to analyse the differences between survival curves. Cox’s
proportional hazards model in a forward stepwise manner with the log-likelihood ratio
significance test was used in the multivariate analysis to examine the independent
prognostic value of the variables (399). Disease-related survival (DRS) was defined as
the time interval between the date of surgery and the date of death due to ovarian
cancer. Recurrence-free survival (RFS) was defined by the time interval between the
date of surgery and the date of recurrence. Probability values less than 0.05 were
considered as significant in the analyses.
4.6. Ethics
The research was approved by the National Authority for Medicolegal Affairs (N:o
2953/32/300/03) and by the research ethical committee of Kuopio University and
Kuopio University Hospital (N:o 4/2003).
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5. RESULTS
5.1 Patient characteristics (I-IV)
The clinicopathological characteristics and the treatment of the patients are summarised
in Table 5. The median follow-up time of all the patients included in the study (n=310)
was 28 months (range 0.3 to 334 months), and for surviving patients (n=79) it was 139
months (range 12 to 334 months). The mean age of the patients at the time of diagnosis
was 60 years with a median age of 62 years (range 18 to 85 years). Of the 310 study
patients, 264 (85%) were treated by chemotherapy, which was based on platinum in 164
cases (53% of the study population and 62% of the patients treated by chemotherapy). A
secondary operation was performed on 121 (39%) of the patients. During the first ten
years of follow-up, 76 patients (24%) with an initial complete response for treatment
were known to have suffered a recurrence, 92 patients (30%) were without recurrence,
the tumour was present or progressing in 129 patients (42%), and data about recurrence
were missing from 13 (4 %) patients. Sixty seven (85%) of the patients alive after ten
years were recurrence-free. At the end of the 10-year follow-up, 199 patients (64%) had
died of ovarian cancer and 32 patients (10%) were dead because of other causes. The
10-year disease-related survival rate of the patients was 32%, and the median survival of
the patients was 33 months (95% CI 26-41 months). The 10-year recurrence-free
survival rate was 51%.
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Table 5. Clinicopathological data of the 310 patients included in the separate studies (I-IV).
Characteristic I II III IV
N % N % N % N %
Number of patients 299 100 305 100 301 100 175 100
Follow-up time (months)
   Median (range) 27 (1-334) 28 (1-334) 29 (0.3-334) 23 (1-327)
Age, years
   Median (range) 62 (18-85) 62 (18-85) 62 (18-85) 61 (21-83)
FIGO stage
   I 83 28 84 28 84 28 31 18
   II 46 15 47 15 46 15 27 15
   III 138 46 142 47 140 47 95 54
   IV 32 11 32 10 31 10 22 13
Histological subtype
   Serous 107 36 107 35 106 35 71 40
   Mucinous 29 9 33 11 28 9 17 10
   Endometrioid 80 27 80 26 82 27 46 26
   Clear cell 32 11 32 10 32 11 17 10
   Miscellaneous* 51 17 53 18 53 18 24 14
Histological grade
   1 40 13 44 14 40 13 23 13
   2 101 34 104 34 103 34 63 36
   3 158 53 157 52 158 53 89 51
Primary residual tumour
   None 120 40 122 40 121 40 53 30
<2 cm 50 17 51 17 51 17 36 21
   >2 cm 103 34 106 35 103 34 70 40
   No data 26 9 26 8 26 9 16 9
Post-operative treatment
   None 36 12 37 12 35 11 3 2
   Chemotherapy 218 73 223 73 219 73 152 86
   Radiotherapy 9 3 7 2 9 3 3 2
   Both 36 12 38 13 38 13 17 10
Adjuvant chemotherapy
   Platinum-containing therapy 159 53 161 53 158 53 155 89
   Non-platinum therapy 92 31 97 32 96 32 14 8
   None 45 15 44 14 44 14 6 3
   No data 3 1 3 1 3 1 0 0
Chemotherapy response#
   PR 38 13 38 13 38 13 28 16
   CR 135 45 140 46 137 46 86 49
   SD 19 7 22 7 22 7 14 8
   PD 55 18 54 18 53 18 38 22
   No chemotherapy 45 15 44 14 44 14 6 3
   No data 7 2 7 2 7 2 3 2
Tumour recurrence at 10 years
   No recurrence 89 30 91 30 91 30 43 25
   Recurrence 74 25 75 25 73 25 44 25
   Tumour present/progressing+ 123 41 126 41 124 41 82 47
   No data 13 4 13 4 13 4 6 3
Cause of death at 10 years
Ovarian cancer 191 64 195 64 191 64 120 68
   Other cause 31 10 32 10 31 10 17 10
   Alive 77 26 78 26 79 26 38 22
*includes 1 malignant Brenner tumour in studies I-III, 20 mixed epithelial tumours in studies I-
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III and 9 in study IV, and 30, 32, 32, 15 unclassified epithelial tumours in studies I-IV,
respectively
#CR=complete response, PR=partial response, SD=stable disease, PD=progressing disease
+includes patients without response to primary treatment and with residual tumour
Table 6. Clinicopathological characteristics of the patients treated with platinum-based
chemotherapy (N=164) and of those treated with non-platinum based or no chemotherapy
(N=143).
Platinum-based chemotherapy
N (%)
Non-platinum-based/
none chemotherapy
N (%)
FIGO stage
   I 27 (17) 58 (40)
   II 23 (14) 24 (17)
   III 92 (56) 50 (35)
   IV 22 (13) 11 (8)
Histological grade
   1 19 (12) 27 (19)
   2 60 (36) 42 (29)
   3 85 (52) 74 (52)
Histological subtype
   Serous 65 (39) 43 (30)
   Mucinous 19 (12) 14 (10)
   Endometrioid 41 (25) 40 (28)
   Clear cell 15 (9) 17 (12)
   Miscellaneous 24 (15) 29 (20)
5.2. Expressions of biological factors
5.2.1. Versican (I)
Epithelial cells of normal ovaries (n=6) were invariably versican negative, and versican
staining in the normal ovarian stroma was generally of weak intensity. In ovarian
cancer, cancer cell-associated versican signal was observed in 50.5% (n= 151) of the
samples, although the percentage of positive cells remained low (<5% in 77.3% of the
samples). Versican positivity in cancer cells was localised mainly in the cytoplasm or on
the plasma membrane (n=138) but in a few cases (n=13) there was also nuclear
localisation. In ovarian cancer stroma, the high intensity of versican staining was
relatively frequent, and 133 (44.5%) and 166 (55.5%) tumours fell into the low and high
(Figure 4A) expression level categories, respectively. No significant difference was
found in cancer cell-associated (z=-1.5, p=0.13; Wilcoxon test) or strong stromal (z=-
1.1, p=0.28) versican expression between primary tumours and metastases.
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5.2.2. E-cadherin-catenin complex (II)
The expression of E-cadherin and b- and g-catenins was located mainly on the cancer
cell membrane either continuously or uncontinuously (Figure 4B). The mean percentage
of strong continuous membranous expression in primary tumours was 9%, 7% and 7%,
and in metastases 10%, 5% and 6% for E-cadherin, b- and g-catenins, respectively.
Strong continuous membranous staining was limited to 5% or fewer cancer cells in the
majority of cancer samples (n=204 (72%) for E-cadherin, n=228 (77%) for b-catenin,
and n=218 (74%) for g-catenin).
   In addition to membranous staining, nuclear staining was seen in a few primary
tumour samples (n=23 (8%) for b-catenin (Figure 4C), and n=52 (18%) for g-catenin).
Sixteen of 23 primary samples (70%) expressing nuclear b-catenin were of
endometrioid histological subtype. In metastases, nuclear positivity for b-catenin was
observed in 1 (2%) endometrioid tumour sample and for g-catenin in 2 (5%) samples.
There were no significant differences in E-cadherin (z=-0.3, p=0.80), b-catenin (z=-0.4,
p=0.68) and g-catenin (z=-1.9, p=0.054) expression patterns between primary tumours
and metastases.
5.2.3. iNOS (III)
The expression of iNOS was detected in the cancer cell cytoplasm as granular deposits
(Figure 4D), and also in mononuclear inflammatory cells in cancerous stroma. The
mean percentage of iNOS positive cells was 50% in primary tumours (n=301), and 62%
in metastases (n=43). Nonetheless, twelve (4%) of the primary tumours and 2 (0.6%) of
the metastases were completely iNOS-negative. The intensity of the expression was
strong in 37% of the primary tumours. Interobserver agreement (observers M.A, S.M.)
for the intensity of the iNOS staining was moderate (Kappa value 0.6, p<0.0005). iNOS
expression of the primary tumours did not differ significantly from that of the matched
metastatic lesions (z=-0.61, p=0.54).
5.2.4. CD34 as evaluated by the Chalkley method (IV)
The median Chalkley count was 7.67 for primary tumours and 8.17 for metastases
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(range 4.00-19.00 and 6.00-15.00, respectively). Of the 175 primary samples, ninety one
(52%) had a Chalkley count <8 (low expression group, Figure 4E), and eighty four
(48%) >8 (high expression group, Figure 4F). There was no significant difference in the
Chalkley count between the primary tumours and the metastases (z=-1.9; p=0.057). The
coefficient of variation was 12% for intraobserver and 22% for interobserver variability.
5.3. Interrelationships between biological factors
Stromal versican expression was correlated with stromal hyaluronan expression, and an
unsubstantial correlation was found between cancer cell-associated versican and CD44
(Table 7).
   Membranous expressions of E-cadherin and b- and g-catenins were correlated with
each other, and the expression of g-catenin on cell surface was related to ?-catenin
expression (Table 7). A very weak correlation of membranous b-catenin staining was
observed with cancer cell-associated versican expression and inversely with strong
stromal versican expression. Membranous expressions of b- and g-catenins were both
inversely weakly correlated with strong stromal hyaluronan expression (Table 7).
Nuclear g-catenin positivity was associated with positivity for hyaluronan in cancer
cells, whereas nuclear b-catenin positivity was associated with high CD44 expression
(Table 7), with this association being particularly clear in endometrioid tumours (c2,
p<0.0005).
   iNOS expression correlated weakly with CD44 expression as well as membranous E-
cadherin expression (Table 7). CD34 expression, as reflected in the Chalkley count, was
weakly related to cancer cell-associated versican expression (Table 7).
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Figure 4. A) A serous ovarian carcinoma representing a high level of strong versican expression
in stroma (asterisk). Scale bar=250µm. B) Preserved expression of E-cadherin on the cancer cell
membrane (arrows) of a serous ovarian cancer. Scale bar=250µm. C) An endometrioid ovarian
cancer with nuclear b-catenin expression (arrow). Scale bar=100µm. D) Expression of iNOS as
granular deposits in the cancer cell cytoplasm of a serous ovarian carcinoma with a high level of
iNOS expression. Also the strong intensity of iNOS expression is seen (arrow). Scale
bar=100µm. E) Low CD34 expression in terms of the Chalkley count seen in a serous ovarian
carcinoma. Tumour vessel is marked by the arrow. Scale bar=250µm. F) High expression of
CD34 is shown in an endometrioid ovarian cancer. The arrows mark tumour vessels. Scale
bar=250µm. Stromal area is indicated by the asterisk in each figure.
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5.4. Association of biological factors with the clinicopathological variables
5.4.1. Versican (I)
A high proportion of strong stromal versican was associated with serous histological
subtype, advanced FIGO stage and large (>2 cm) primary residual tumour. Versican
positivity in tumour cells was correlated with clear cell histological subtype, early FIGO
stage and the absence of primary residual tumour (Table 8).
5.4.2. E-cadherin-catenin complex (II)
Reduced E-cadherin and b-catenin expression on tumour cell membrane was associated
with serous and endometrioid histological subtypes, poor differentiation and cancer
recurrence. In addition, reduced cell surface expression of b-catenin was associated with
advanced FIGO stage and large (>2cm) primary residual tumour. Nuclear positivity for b-
catenin was related to endometrioid histological subtype, good-to-moderate differentiation
and early FIGO stage of the tumour (Table 8).
   Reduced membranous expression of g-catenin was correlated with serous and
endometrioid histological subtypes and large (>2cm) primary residual tumour. Nuclear g-
catenin expression was associated with serous histological subtype, poor differentiation of
the tumour and a better response to chemotherapy (Table 8).
5.4.3. iNOS (III)
High iNOS expression was significantly correlated with mucinous histological subtype,
whereas low iNOS expression was associated with large (>2cm) primary residual tumour
and cancer recurrence (Table 8).
5.4.4. CD34 as evaluated by the Chalkley method (IV)
A low Chalkley count was related to serous and clear cell histological subtypes but not to
any of the other studied clinicopathological factors (Table 8).
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Table 8. Relation of biological factors to clinicopathological variables (c2-test).
Marker Histological
subtype
Histological
grade
FIGO
stage
Residual
tumour
Chemotherapy
response
Recurrence
at 10 years
End
state
Versican
(cells)
p<0.0005 ns p=0.015 p=0.006 ns ns ns
Versican
(stroma)
p=0.019 ns p<0.0005 p=0.002 ns ns ns
E-cadherin
(membrane)
p<0.0005 p=0.005 ns ns ns p=0.014 ns
b-catenin
(membrane)
p<0.0005 p=0.009 p=0.002 p=0.008 ns p=0.049 ns
b-catenin
(nuclear)
p<0.0005 p=0.025 p=0.027 ns ns ns ns
g-catenin
(membrane)
p<0.0005 ns ns p=0.009 ns ns ns
g-catenin
(nuclear)
p=0.002 p=0.009 ns ns p=0.028 ns ns
iNOS p=0.009 ns ns p=0.007 ns p=0.038 ns
CD34 p<0.0005 ns ns ns ns ns ns
5.5. Prognostic factors of the study patients
5.5.1. Clinicopathological factors (I-IV)
The prognostic value of clinicopathological parameters and biological factors was
evaluated in relation to disease-related survival as well as to recurrence-free survival. In
univariate survival analysis of the whole study cohort, the significant factors predicting
poor disease-related and recurrence-free survival were advanced FIGO stage, poor
differentiation and serous histological subtype of the tumour, and the presence as well as a
larger size (>2cm) of the primary residual tumour (Table 9).
   When only patients treated with platinum-based chemotherapy were included in the
univariate analysis, the significant factors predicting poor disease-related survival were
advanced FIGO stage, poor differentiation and the presence and larger size (>2cm) of
primary residual tumour. The significant predictors of poor recurrence-free survival were
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advanced FIGO stage, serous histological subtype as well as the presence and a larger size
(>2cm) of the primary residual tumour (Table 10).
Table 9. Summary of the prognostic value of clinicopathological factors in univariate survival
analyses of the whole patient group. p-values are from log-rank analyses.
Variable N DRS N RFS
Histological grade 300 p<0.0005 163 p=0.034
FIGO stage 300 p<0.0005 163 p<0.0005
Histological subtype 300 p=0.039 163 p=0.007
Primary residual tumour 276 p<0.0005 155 p<0.0005
Age at diagnosis 300 p=0.005 163 ns
Adjuvant chemotherapy 297 p=0.024 162 ns
Table 10. Summary of the prognostic value of clinicopathological factors in univariate survival
analyses of the patients treated with platinum-based chemotherapy. p-values are from log-rank
analyses.
Variable N DRS N RFS
Histological grade 164 p=0.020 79 ns
FIGO stage 164 p<0.0005 79 p=0.001
Histological subtype 164 ns 79 p=0.036
Primary residual tumour 151 p<0.0005 76 p=0.0001
Age at diagnosis 164 ns 79 ns
5.5.2. Biological factors and survival
5.5.2.1. Versican (I)
Increasing (>15%) strong stromal versican was a predictor of worse disease-related survival
in the univariate analysis during the first five years of the follow-up (p=0.032), but lost its
significance when the follow-up was prolonged up to ten years. Instead, the recurrence-free
survival at ten years was significantly better in the univariate analysis when the tumour
epithelium was versican positive, compared to negative epithelium (Table 11). Versican
60
expression had no prognostic value in the subgroup of the patients treated with platinum-
based chemotherapy (Table 12). In multivariate analysis of the study I material, neither
stromal nor cancer cell-associated versican expression exhibited any prognostic
significance in DRS or in RFS at five or ten years.
5.5.2.2. E-cadherin-catenin complex (II)
In univariate analysis of the whole study material, preserved b-catenin expression on cell
surface predicted better 10-year disease-related and recurrence-free survival. In addition,
favourable recurrence-free survival in univariate analysis was indicated by preserved E-
cadherin and marginally by preserved g-catenin expression on tumour cell membrane
(Table 11). Nuclear b- and g-catenin positivities (n=14 and n=10, respectively) were
significant predictors of better 10-year disease-related survival in univariate analysis in the
subgroups of 76 (b-catenin) and 77 (g-catenin) endometrioid ovarian cancers (p=0.008 and
p=0.012, respectively) but were not significantly associated with recurrence-free survival of
the patients. None of the E-cadherin-catenin complex components retained their statistical
significance in predicting DRS or RFS in the multivariate analyses performed in study II.
   In univariate analysis of the patients treated with platinum-based chemotherapy, better
10-year recurrence-free survival was predicted significantly by preserved b-catenin
expression and marginally by preserved g-catenin expression on the cell surface (Table 12).
In addition, nuclear b- or g-catenin positivities were not significant prognostic factors in the
subgroup of endometrioid ovarian cancers.
5.5.2.3. iNOS (III)
High iNOS expression was associated with better disease-related survival in univariate
analysis of the whole study material (Table 11) but possessed no prognostic value in the
subgroup of the patients treated with platinum-based chemotherapy (Table 12) nor did it
retain its statistical significance in predicting prognosis in multivariate analysis of the study
III.
61
5.5.2.4. CD34 as evaluated by the Chalkley method (IV)
The Chalkley count was not significantly related to disease-related or recurrence-free
survival in the univariate analysis of the entire study cohort (Table 11) or in the subgroup of
the patients treated with platinum-based chemotherapy (Table 12). Instead, the high
Chalkley count predicted poor disease-related survival in FIGO stage III-IV tumours
(p=0.007). In multivariate analysis of the study IV, the high Chalkley count was an
independent predictor of poor DRS in the entire study group (n=156; p=0.044, RR=1.50,
95% CI 1.01-2.21) but was not a significant predictor of RFS.
Table 11. Summary of 10-year prognostic significance of the tested biological factors in univariate
survival analyses of the whole study material. p-values are from log-rank analyses.
Factor N DRS N RFS
Versican (cells) 289 ns 158 p=0.027
Versican (stroma) 289 ns 158 ns
E-cadherin 273 ns 149 p=0.038
b-catenin (membrane) 286 p=0.035 154 p=0.033
b-catenin (nuclear) 286 ns 154 ns
g-catenin (membrane) 283 ns 150 p=0.053
g-catenin (nuclear) 283 ns 150 ns
iNOS 291 p=0.009 159 ns
CD34 174 ns 87 ns
Table 12. Summary of 10-year prognostic significance of the tested biological factors in univariate
survival analyses of the patients treated with platinum-based chemotherapy. p-values are from log-
rank analyses.
Factor N DRS N RFS
Versican (cells) 159 ns 76 ns
Versican (stroma) 159 ns 76 ns
E-cadherin 152 ns 74 ns
b-catenin (membrane) 159 ns 79 p=0.043
b-catenin (nuclear) 159 ns 79 ns
g-catenin (membrane) 158 ns 76 p=0.051
g-catenin (nuclear) 158 ns 76 ns
iNOS 158 ns 78 ns
CD34 155 ns 77 ns
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5.5.3. Conclusive multivariate analyses of the whole study material
The clinicopathological factors predicting independently disease-related survival in
separate studies I-IV were FIGO stage, histological grade, and primary residual tumour. In
addition, first line chemotherapy predicted disease-related survival in study I. The
independent prognosticators of recurrence-free survival were primary residual tumour and
histological subtype in each study. CD34 expression as evaluated with the Chalkley count
was found to be a new significant and independent prognostic factor for DRS in the whole
study IV material. All these variables were included in the multivariate analysis to test the
independent prognostic value of each factor. In this way, the independent prognostic factors
in the whole study cohort were primary residual tumour and CD34 expression for DRS, and
histological subtype as well as primary residual tumour for RFS (Table 13).
   Similarly, analysing the subgroup of patients treated with platinum-based chemotherapy
in the multivariate analysis resulted in identification of the independent prognostic
significance of primary residual tumour and CD34 expression for DRS, whereas only
primary residual tumour predicted RFS (Table 14).
   When hyaluronan, which has been previously shown to be an independent prognostic
factor (167), was included in the multivariate analysis of the whole study group, the
significant factors predicting poor DRS (n=156) were the presence of primary residual
tumour (p<0.0005, RR=4.69, 95% CI 2.79-7.90) and a high level of strong stromal
hyaluronan expression (p=0.024, RR=1.59, 95% CI 1.06-2.38), and poor RFS (n=82) was
predicted by serous histological subtype (p=0.034, RR=2.01, 95% CI 1.05-3.82), the
presence of primary residual tumour (p=0.001, RR=3.36, 95% CI 1.68-6.71), and a high
level of strong stromal hyaluronan expression (p=0.029, RR=2.05, 95% CI 1.08-3.90). In
the subgroup of patients treated with platinum-based chemotherapy, independent poor
prognostic factors were advanced FIGO stage (p=0.034, RR=2.01, 95% CI 1.06-3.83), the
presence of primary residual tumour (p=0.001, RR=3.53, 95% CI 1.71-7.26) and high level
of strong stromal hyaluronan expression (p=0.005, RR=1.81, 95% CI 1.19-2.76) for DRS
(n=142), and the presence of primary residual tumour (p<0.0005, RR=4.21, 95% CI 1.99-
8.88) as well as high level of strong stromal hyaluronan expression (p=0.011, RR=2.42,
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95% CI 1.23-4.75) for RFS (n=74).
Table 13. Independent predictors of 10-year disease-related (n=156) and recurrence-free (n=82)
survival in the Cox's multivariate analysis of the whole study patient group.
Factor Category RR 95% CI p-value
Disease-related survival
   Primary residual tumour Negative vs. positive 0.20 0.12-0.33 <0.0005
   CD34 expression Low vs. high 0.67 0.45-0.99   0.043
Recurrence-free survival
   Histological subtype Serous vs. others 2.14 1.12-4.06   0.021
   Primary residual tumour Negative vs. positive 0.30 0.15-0.60   0.001
*Reference category
RR=relative risk
CI=confidence interval
Table 14. Independent predictors of 10-year disease-related (n=142) and recurrence-free (n=74)
survival in the Cox's multivariate analysis of the patients treated with platinum-based
chemotherapy.
Factor Category RR 95% CI p-value
Disease-related survival
  Primary residual tumour Negative vs. positive 0.16 0.09-0.30 <0.0005
  CD34 expression Low vs. high 0.66 0.44-0.99   0.045
Recurrence-free survival
  Primary residual tumour Negative vs. positive 0.24 0.11-0.50 <0.0005
*Reference category
RR=relative risk
CI=confidence interval
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6. DISCUSSION
6.1. Evaluation of the study material
The current study cohort consists of ovarian cancer patients diagnosed and treated in
Kuopio University Hospital area during the years 1976-1992. The majority of disease
recurrences and the decline in the survival rates occur during the first few years after the
diagnosis (42, 400), and the vast majority of prognostic ovarian cancer studies report 5-year
survival rates. In the present study, the follow-up of the patients was continued until
January 2004, which provides unique survival data up to ten years. The 10-year disease-
related survival of the patients in the present study was 32%, which is considerably higher
than in the few publications which have reported long-term follow-up values (401-403).
These three papers, however, only included advanced-stage patients and differ in this
respect from the present study, but the values of the present study are comparable to the 10-
year survival reported in Finland from the same time period (51). The median follow-up
time of the patients included in the study (n=310) was 28 months, reflecting the bleak
course of the disease. On the contrary, the median follow-up time for surviving patients
(n=79) was rather long, 139 months. The mean age of the patients was 60 years, which is in
line with that reported in the literature (3, 5, 51, 404). The distribution of the patients
according to the histological subtype is different from some reports (3, 45) with a
somewhat smaller proportion of serous type carcinomas in the present study, but
nonetheless falling into the range reported by others (405, 406). Furthermore, the
distribution of the patients according to the FIGO stage (52, 404, 406) and histological
grade (406, 407) is comparable to previous reports so there does not seem to be any notable
selection bias in the present study material.
   Post-operative treatment contained chemotherapy in 85% of the study patients, and was
based on platinum in 62% of these patients. The retrospective nature and the relatively long
entry period for the study from 1976 to 1992 may generate heterogeneity of the patients,
particularly with respect to chemotherapy and staging methods. Consequently, first line
chemotherapy in the present study was based on platinum more frequently in patients
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diagnosed within the last ten years of the study compared to the patients from the former
study period (?2 test), which is in line with the changes in treatment strategies occurring
over that time (408, 409). However, there were no differences with respect to other
clinicopathological variables between these two patient groups. Chemotherapy based on
platinum regimens was received more often by patients with advanced-stage disease and
those with larger (>2 cm) residual disease after primary surgery (?2 test), which is not
surprising given that these were the characteristics also of those patients included in one of
the major studies establishing the advantages of platinum in front-line chemotherapy for
ovarian cancer (410) which certainly affected subsequent treatment decisions.
   The surgical procedure for ovarian cancer has also undergone substantial changes (408)
since the implication of primary residual tumour size as an important prognostic factor (68),
reports of lymph node metastasis in ovarian cancer (62, 411) and the introduction of an
operative staging system (412). Therefore, some understaging may exist in the present
study material. Furthermore, some of the patients had to be excluded from the study
because there was insufficient tumour material available for immunohistochemical
analyses, but no statistical differences in clinicopathological variables existed between the
original cohort of 445 patients and the present study cohort (test of goodness for fit). To
conclude, there does not seem to be any major selection bias in the present study, but the
results must be interpreted with some caution bearing in mind the different treatment
modalities from those of today.
6.2. Evaluation of the study methods
The histological diagnosis was confirmed earlier by re-evaluation of histological subtype
and grade by the same experienced pathologist unaware of the clinical data (128, 395), thus
reducing bias from interobserver variability (413-416). There are some clear problems
associated with immunohistochemistry, since methodological variability, such as
differences in fixation, processing and storage of the tumour tissues as well as different
antibodies and cut-offs used, which can all affect the comparability of the results from
different studies (417-419). All slides in this study were evaluated by one to three observers
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to reach a consensus. In all the staining series, negative controls remained negative and
positive controls stained appropriately. The continuous variables obtained from
immunohistochemical analyses were dichotomised into two categories using the median
value as the cut-off for versican, E-cadherin, ?- and ?-catenins as well as for CD34
expression, and the 66th percentile as the cut-off for iNOS, as the median or some other
centile have been demonstrated to be usable without introducing bias (420).
   The evaluation of angiogenesis was performed with the Chalkley assay, which is
recommended to be used for angiogenesis quantification in solid tumours by international
consensus report (304). In general, this method is considered to be a simple and acceptable
procedure for practical evaluation of intratumoural vascularity and it has been reported to
be objective, rapid and have acceptable reproducibility (312, 319, 321, 421). However, it is
noteworthy that both the Chalkley assay and microvessel counting method suffer from
some methodological problems, for example concerning the objective nature of selection of
the densely vascularised areas, "vascular hot-spots" for microvessel quantitation.
Nevertheless, choosing the same hot-spot areas may not necessarily improve the
reproducibility (421), and since it represents a relative vessel area estimate rather than a
true vessel count, one of the advantages of the Chalkley method is that this eliminates one
of the highly observer-dependent steps in microvessel counting method: the decision
whether two immunostained and adjacent structures are the reflection of one single or two
separate blood vessels (304). Accordingly, the Chalkley method has been shown to have
less observer variation than estimation of microvessel density in breast cancer (421), and
high levels of agreement between two observers have been reported in non-small cell lung
cancer (321, 322) and soft tissue sarcoma (319). Furthermore, it seems to be clearly
superior to the microvessel counting method in the evaluation of breast cancer prognosis
(422). However, the prognostic impact of the two methods seems to vary with the type of
carcinoma (311), and therefore more studies using both methods are needed.
6.3. Clinicopathological prognostic factors in epithelial ovarian cancer
Previously well-defined prognostic value of residual tumour (44-46) was confirmed also in
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the current study. Age at diagnosis appeared to be significant in the univariate analysis but
lost its significance when analysed with the other factors, indicating that those other
variables, e.g. treatment modalities, may affect the prognosis more than simply the age of
the patient. Although age has been shown to predict survival in many studies (3, 45, 50, 51,
145, 407, 423, 424), also a lack of prognostic significance has been shown (425-427). The
diversity of the factors included in survival analyses may at least partly explain the
differences in the results, and the prognostic significance of age may to some extent reflect
the less aggressive treatment that elderly patients receive (54-56).
   Recurrence-free survival was predicted by primary residual tumour and histological
subtype. The histological subtype has been indicated as being an independent
prognosticator in some studies (45, 50, 84, 425, 426, 428, 429), whereas it has lacked
significance in others (70, 407, 430). However, inter- and intraobserver variability probably
affects the results obtained for prognostic significance of histological classification (413-
416, 431-434). In addition, clear deficiencies in the reproducibility of tumour grading by
different pathologists have been reported (413-416) and this may lead to differences
between studies about the prognostic significance of histological grade (92-94). A universal
grading system in analogy to that used for evaluating breast carcinomas has been suggested
(435) and shown to provide independent prognostic information (435-438).
   Since the 70's, numerous studies have shown that residual tumour size has an impact on
patients' survival (44-46, 52, 69-71). The possibility that improved survival of patients with
more extensive cytoreduction may merely reflect the biological features of the tumour has
been under debate. However, since no prospective randomised trials to investigate the
efficacy of initial surgical debulking have been made and would be ethically unjustifiable,
the present data support the effort to achieve maximal cytoreduction with the target of no
macroscopic residual tumour. Indeed, all attempts to debulk the ovarian cancer patient to a
level of no gross residual disease were recommended also by a consensus meeting of
European Society of Gynaecological Oncology (ESGO) (73). The results of the present
study support this conclusion by highlighting the survival advantage for the patients with
no primary residual tumour, which is in line with other studies (3, 71, 73, 74) including a
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prospective study with the goal of removal of all visible disease and improval of survival
for those patients in whom this was achieved (429). Although the treatment with platinum-
based chemotherapy regimen has been indicated to be more powerful predictor of survival
than the extension of primary cytoreductive surgery (51, 439), nowadays when virtually all
the patients receive platinum-based chemotherapy, it is more crucial to define the
prognostic significance of the primary cytoreductive surgery. In the current study, the
presence of primary residual tumour was an independent predictor of survival in the whole
study group as well as in the patient group treated with platinum-based chemotherapy
which is in line with the results from a large meta-analysis of 6885 patients (69).
Furthermore, in pursuit of better surgical outcomes, centralisation of ovarian cancer
treatment and subspeciality training of the surgeons have been shown to result in the
highest rates of optimal cytoreduction and comprehensive staging (404, 440) and may
further improve the survival rates of ovarian cancer patients (440, 441).
6.4. Extracellular matrix and cell adhesion molecules in epithelial ovarian cancer
6.4.1. Versican
Previously, stromal hyaluronan has been shown to have independent prognostic value in
epithelial ovarian cancer (167), and versican has been shown to bind hyaluronan (204). In
the present study, increasing strong stromal versican staining was a predictor of worse
disease-related survival in univariate analysis during the first five years of the follow-up,
but had no independent prognostic impact when analysed in conjunction with the
clinicopathological factors. This is in line with the findings of disease-free survival of
breast cancer (211) and adenocarcinomas of the lung (218). In addition, versican lost also
its univariate significance when the follow-up was prolonged to ten years.
   In general, versican expression appears to be elevated in the cancer samples as compared
to normal ovaries, and stromal versican expression increases with advancing stage of
ovarian cancer. These results suggest that versican may have a potential role in the
development and progression of ovarian cancer, although it may not be a good predictor of
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prognosis. A high level of stromal versican was correlated with a high stromal hyaluronan
level, which points to a parallel influence of versican and hyaluronan on the cancer
progression. However, the prognostic value in epithelial ovarian cancer seems to be better
for hyaluronan (167), and the prognostic influence of versican may be more relevant in
other cancer types (212, 213, 219, 220).
6.4.2. E-cadherin-catenin complex
Membranous expression of b-catenin was found to have a weak inverse correlation to
strong stromal hyaluronan, consistent with the observation that cells overexpressing HAS2
show a marked decrease in intensity of staining at the intercellular boundaries and a diffuse,
cytoplasmic distribution of b-catenin (442). In addition, hyaluronan may induce a b-catenin
shift from the cell-cell adhesion state leading to nuclear translocation in ovarian cancer
cells (443). The present study revealed a significant correlation between nuclear b-catenin
expression and high CD44 expression, which is in line with the implication that the
expression of CD44 is regulated by b-catenin/Tcf-4 through enhanced transcription of
CD44 (444). As stated earlier, dysregulation of b-catenin leading to its nuclear
accumulation is a common feature of endometrioid type ovarian cancer (253, 445, 446),
and accordingly, also the association between nuclear b-catenin expression and CD44 was
focused especially on endometrioid ovarian carcinomas. Although also versican gene
expression has been shown to be up-regulated via the b-catenin-Tcf complex formation in
smooth muscle cells (447), no association was observed between nuclear b-catenin and
versican expression. However, gene expression may be regulated by a number of different
factors and the role of b-catenin in the regulation of versican expression in ovarian cancer
remains to be clarified.
   Previous prognostic studies on E-cadherin-catenin complex in ovarian cancer have
resulted in uncertainty about the prognostic significance of the complex (186, 232, 248-
254). In the present study, preserved membranous expression of E-cadherin indicated better
10-year recurrence-free survival in the univariate analysis, a result in agreement with some
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previous studies (186, 248, 249), but not with one study (232). Preserved b-catenin
expression on cell surface indicated better 10-year disease-related and recurrence-free
survival in univariate analysis, which is in line with one previous study (250) but
contradicted by others where no relationship was found between membranous b-catenin
expression and survival (232, 252, 253). Nuclear positivity of b-catenin predicted better
disease-related survival for patients with endometrioid ovarian cancers, and an association
between accumulated nuclear b-catenin expression and a favourable prognosis has been
reported in ovarian cancer also previously (252, 253). However, in serous ovarian cancer,
the opposite trend has been reported (254), possibly reflecting the differences in the
molecular pathways underlying the tumourigenesis of different histological subtypes (154).
Accordingly, different cadherin-catenin expression patterns are associated with distinct
histologic subtypes (446). Indeed, nuclear b-catenin accumulation has been found to be
characteristic for endometrioid tumours, and mutations of the gene encoding b-catenin,
CTNNB1, have been reported in 16-54% of endometrioid ovarian carcinomas (252, 445,
448-451), leading to nuclear accumulation of b-catenin. Tumours associated with such
mutations and nuclear b-catenin positivity have been found to be more frequently low-
grade and stage, and accordingly, to have a favourable prognosis (252, 253, 445) in line
with the present findings. The results suggest that modulation of the Wnt signalling
pathway may be one mechanism involved in the tumourigenesis of endometrioid ovarian
carcinomas.
   In addition, nuclear g-catenin positivity was found to be a significant prognosticator of
better 10-year disease-related survival in univariate analysis in the subgroup of
endometrioid ovarian cancers. Previously, nuclear g-catenin positivity has been observed
immunohistochemically in endometrial (452), renal cell (453) and non-small cell lung (454)
carcinomas. Although mutations of the g-catenin gene have been suggested to be rare in
patients with ovarian cancer (445, 455), the subregion of chromosome 17 that includes g-
catenin gene is known to be particularly subjected to genetic alterations in sporadic ovarian
tumours (456), and nuclear g-catenin positivity has been reported recently also in other
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ovarian carcinoma studies (186, 446). Furthermore, g-catenin can activate the Wnt
signalling cascade directly without any interaction of b-catenin, since it possesses multiple
functions as a transcriptional activator and a cell adhesion molecule like b-catenin (457),
thus lending support to its possible role in regulating cell functions. While the prognostic
significance of nuclear g-catenin expression appears to be lacking in other cancers (453,
454) and remains to be confirmed in ovarian cancer, it is concluded that none of the E-
cadherin-catenin complex components could overcome the prognostic significance of
traditional clinocopathological factors in multivariate analysis of the present study.
6.5. Angiogenesis in epithelial ovarian cancer
6.5.1. iNOS
Hyaluronan has been suggested to induce iNOS expression by activation of the
transcriptional regulator nuclear factor kappaB (458). In the current study, there was no
association between the expressions of iNOS and hyaluronan. However, the stimulative
effect of hyaluronan on iNOS mRNA has been shown to be dependent on the hyaluronan
size (458-460), which may restrict the evaluation of the relationship with the method used
in the present study which did not differentiate between different size hyaluronan
molecules. On the other hand, a weak correlation was found between iNOS and CD44
expression in cancer cells, which might reflect the regulation of iNOS expression through
CD44-hyaluronan interactions (459, 460).
   Although iNOS has been indicated to be important for angiogenesis promotion also in
ovarian cancer in vitro (461), the high concentration of NO that is produced by iNOS may
inhibit proliferation of endothelial cells and vascular smooth-muscle cells (462). Unlike in
gall-bladder (463), gastric (464), colorectal (465) and endometrial (466) carcinomas, in the
present study there was no correlation between iNOS expression and angiogenesis as
determined here by the Chalkley count after CD34 staining. However, Özel et al. (279)
have previously reported similar findings of a missing association between iNOS and
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microvessel density in ovarian cancer. In addition to methodological disparities, the
biological differences regarding these cancers are also likely to explain the conflicting
results between the studies.
   Previously, iNOS expression has been reported to be an independent marker for poor
survival in FIGO stage III, poorly differentiated serous ovarian carcinoma (278). On the
contrary, in another ovarian cancer study with 100 patients, the median survival time of
patients with low iNOS expression was shorter than that of those with high iNOS
expression tumours, though the difference failed to reach statistical significance (279). In
the present study with 301 samples available for iNOS analysis, high iNOS expression was
found to associate with better disease-related survival in univariate analysis. This is in
contrast with the results obtained in some studies with different malignancies (273, 282),
but consistent with others (272, 467), though also many studies with a lack of prognostic
significance have been reported (275, 468, 469). Interestingly, nitric oxide has been shown
to have a dual role in tumour progression and metastasis, being able to both promote and
inhibit these processes, depending on the NO-sensitivity of the tumour cells. In turn, this is
thought to be determined by the expression level, duration and timing of NO delivery, the
microenvironment, the genetic background and the cell type (269). With relation to ovarian
cancer, both exogenously applied NO and endogenously synthesised NO have been shown
to inhibit tumour growth, probably mainly by induction of tumour cell apoptosis (470-472),
supporting the present finding of a favourable survival influence of iNOS in ovarian cancer.
Indeed, different malignancies may exhibit divergent sensitivities to NO, which in addition
to methodological differences might explain the conflicts between the different studies.
However, iNOS expression did not retain its statistical significance in predicting prognosis
in the multivariate analysis of this representative material, suggesting that the associations
are too weak to resist the confounding factors that come from different evaluation methods
and clinicopathological features of the cancer materials used by different groups. Moreover,
considering the transient nature of iNOS expression (473) and the single time point
representation of that in a sample of heterogeneous material, only a large material, such as
in the present study with sufficient number of samples in the same phase of expression,
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may provide relevant information on the association between iNOS expression and
survival. Indeed, the importance of clinicopathological factors remains superior to iNOS
expression in prediction of the prognosis of ovarian cancer.
6.5.2. CD34
Interestingly, both the development of a vascular supply and stromal support are essential
for tumour growth. Indeed, the factors important for stromal structure have been associated
also with the regulation of angiogenesis. For example, degradation products of hyaluronan
have been shown to induce an angiogenic response (163). However, in the present study
hyaluronan expression was not related to angiogenesis as estimated by the Chalkley count.
It is possible that different subtypes of hyaluronan synthases may synthesise hyaluronans
with different biological functions, which are not distinguishable by the staining technique
used. Additionally, it is the degradation products of hyaluronan that have been found to
stimulate angiogenesis, whereas high-molecular-weight hyaluronan has been claimed to
inhibit angiogenesis (163), also complicating the evaluation of this interrelationship since
the current method can not differentiate between these species. Furthermore, the
contribution of hyaluronidase to tumour progression through the production of hyaluronan
degradation products and their angiogenic activity may not be as significant in epithelial
ovarian cancer (474) as has been suggested for prostate (173) and bladder (475) tumours.
Indeed, in spite of the missing association between the hyaluronan expression and
angiogenesis in this study, hyaluronan metabolism may play an important regulatory role in
the control of normal and pathological neovascularisation in cell-type specific way.
In the present study, CD34 expression was weakly associated with cancer cell-associated
versican expression. In line with this concept, versican has been claimed to enhance
angiogenesis by stimulating endothelial cell adhesion, proliferation, and migration,
probably through upregulation of and an interaction with fibronectin and VEGF (267).
However, a more detailed role of versican in the regulation of angiogenesis remains to be
elucidated.
   The prognostic significance of angiogenesis as evaluated by microvessel density has
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remained controversial in ovarian cancer multivariate studies, as some studies have shown
that increased angiogenesis predicts either poor (289, 305, 306, 309) or improved survival
(286, 307, 308), whereas a lack of association between angiogenesis and outcome of the
patients has been reported in several studies (284, 288, 290-294, 297, 298, 310). In the
present study, high CD34 expression assessed by the Chalkley evaluation method was
shown to be an independent predictor of poor disease-related survival in the whole study
cohort as well as in the subgroup of patients treated with platinum-based chemotherapy.
However, these results are not directly comparable to those reported earlier because of the
different methodology, although the modified Chalkley method has been used by
Hollingsworth et al. and that group found no prognostic value in their considerably smaller
study group (305). However, the Chalkley method has been claimed to be of benefit in
evaluating other carcinomas. Especially in breast carcinoma, the association of poor
outcome with increasing angiogenesis has been demonstrated (311-314), with only a few
studies failing to detect this link (315, 316). In other types of malignancies, the method has
been shown to have prognostic significance (317, 318), lack significance (319, 320) or its
prognostic significance has remained controversial (311, 321-324). In addition to the lack
of standardised techniques and the impact of that factor on the divergencies, the appearance
of the vascularity seen in studies is attributable to complex processes which are still largely
unclear. Therefore, part of the explanation as to why estimates of tumour angiogenesis do
not consistently indicate poor or favourable prognosis in numerous studies could be that the
biology of angiogenesis is different in different tissues. Indeed, the degree of angiogenesis
seems to vary in different carcinomas, as appears to be the case between ovarian and breast
carcinoma with a lower degree of angiogenesis in the former cancer type (476).
   Chemotherapy resistance still remains as a great obstacle to success in the treatment of
ovarian cancer. Angiogenesis has been linked to chemotherapy response with the
hypothesis of improving delivery of chemotherapeutic agents with increasing angiogenesis.
However, studies have failed to confirm this hypothesis i.e. on one hand increased
angiogenesis has been reported to associate with improved chemotherapy response in
advanced-stage ovarian cancer patients (287), but on the other hand an inverse association
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between vascularity and response to platinum-based chemotherapy has been claimed to
exist (291, 302). In the current study, no association was found between CD34 expression
and response to chemotherapy. Despite increased vascularity, the delivery capacity may be
insufficient due to structural and functional abnormalities of the tumour blood vessels,
leading to chaotic blood flow and making certain regions inaccessible to drugs (477).
Furthermore, malignant cells including ovarian cancer cells, may also participate in
vascular channel formation independent of endothelial cells (478, 479), and these kinds of
structures may remain unlabelled in endothelial marker stainings (480) despite their
possible involvement in drug delivery. Accordingly, evaluation of drug delivery capacity
by assessing only vessel quantities is questionable, and it remains to be determined in the
future whether some angiogenesis marker could help in clinical practice to pinpoint those
patients likely to benefit from anticancer drug therapies.
6.6. Future directions
Tumourigenesis is a multistep process with an accumulation of multiple genetic alterations
(481). Therefore, it is unlikely that an alteration in a single gene has predictive value by
itself. This is supported by the fact that many studies have not found any association
between p53 expression and survival in multivariate analysis (139-150, 482). Instead, it is
probable that the combination of many genetic alterations has greater importance.
Expression of thousands of genes can be assayed with the use of DNA microarray analysis
(483), and this holds the potential to clarify the genetic origins of ovarian cancer. In view of
the fact that chemotherapy resistance severely impedes efficient treatment of ovarian cancer
patients, understanding the biological mechanisms underlying this process could facilitate
improvement of the treatment and outcome of ovarian cancer by directing the treatment
choices or by leading to therapies targeted toward particular molecular subsets (484).
Interestingly, gene expression profiling has provided preliminary data about potentially
important molecular markers for assessing the chemotherapy response (484-489) and
prognosis (487, 489, 490) of ovarian cancer patients, thus providing candidate targets for
prospective trials, hopefully translating into clinical practice and better patient outcome in
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the future.
   While the knowledge of ovarian cancer biology undoubtedly will increase rapidly and
carries with it a chance for more effective treatment modalities, endeavours for such are
constantly ongoing. In order to achieve a more favourable treatment outcome, more
effective combinations of established chemotherapeutic agents as well as entirely new
cytotoxic agents are being evaluated (491), as are also strategies such as consolidation and
maintenance therapy, though these regimens have not yet achieved any significant
improvement in survival, whereas intraperitoneal drug delivery has resulted in notable
promises of survival extension (491, 492). In addition, molecular-targeted therapies in
ovarian cancer are under investigation (491). Taking into account the prognostic value of
angiogenesis in the present study, albeit requiring confirmation in prospective studies
before it is of clinical value, an intriguing subject in this field surrounds the potential of
antiangiogenic treatment. The promising antitumour activity for bevacizumab, i.e. an
antibody to VEGF, has already been reported (493) and will hopefully be further
corroborated in the ongoing clinical trials (493). Additionally, other agents with
antiangiogenic effects, such as enzastaurin (491) are being studied and are of interest since
it is feasible that the combination of multiple antiangiogenesis agents, inhibiting different
steps in the angiogenic cascade may have a synergistic effect (494). Even though the
biological mechanisms underlying angiogenesis still remain largely unknown, the
developments of microarrays hold the potential to identify the angiogenesis-related genes
(494) and enable tailored antiangiogenic therapy.
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7. SUMMARY AND CONCLUSIONS
The present retrospective study was performed in a representative series of ovarian cancer
patients to analyse the distribution and prognostic value of factors related to cell adhesion
and angiogenesis in epithelial ovarian cancer. The independent prognostic significance of
primary residual tumour and histological subtype was confirmed, as was also that of the
previously evaluated stromal hyaluronan expression. In addition to these confirmatory data,
the main findings and conclusions can be stated as follows:
1. The strong stromal versican expression was significantly related to other
clinicopathological factors of poor survival, whereas versican positivity in tumour cells was
correlated with more favourable factors, such as the absence of primary residual tumour
and early FIGO stage. Versican expression was a significant prognostic factor in the
univariate but not in the multivariate analysis.
2. The expression of E-cadherin and b-catenin on cancer cell membrane was significantly
reduced in poorly differentiated and serous or endometrioid histological subtypes, and
expression of b-catenin was reduced also in advanced FIGO stage tumours. Nuclear
positivity of b-catenin was related to early FIGO stage of the disease and to endometrioid
histological subtype, and nuclear positivity of ?-catenin was observed especially in poorly
differentiated and serous tumours. Preserved expressions of E-cadherin and b-catenin, and
marginally also that of ?-catenin on tumour cell membrane, as well as nuclear expression of
b-catenin and ?-catenin in endometrioid ovarian carcinomas were associated with better
outcome of the patients in univariate analysis, but were not significant predictors of
survival in the multivariate analysis.
3. The expression of iNOS was high in the mucinous histological subtype of epithelial
ovarian cancer. A high iNOS expression was a significant favourable prognostic factor in
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the univariate analysis but possessed no independent prognostic value in the multivariate
analysis.
4. Angiogenesis, as determined by the Chalkley method after CD34 staining, was low in
serous and clear cell histological subtypes but was not related to FIGO stage or histological
grade of the tumour, or the presence of primary residual tumour. The high Chalkley count
appeared to be a significant prognostic factor of poor disease-related survival in the
multivariate analysis.
In conclusion, clinicopathological prognostic factors such as primary residual tumour and
histological subtype remain the most important prognosticators of disease progression. In
addition, angiogenesis evaluated here by the Chalkley count, seems to be important in the
progression of epithelial ovarian cancer.
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